Jos Beijnen
#70,964
Most Influential Person Now
Dutch pharmacist and academic
Jos Beijnen's AcademicInfluence.com Rankings
Download Badge
Chemistry
Why Is Jos Beijnen Influential?
(Suggest an Edit or Addition)According to Wikipedia, Jacob Hendrik "Jos" Beijnen is a Dutch pharmacist. He is the hospital pharmacist of the Netherlands Cancer Institute/Antoni van Leeuwenhoekziekenhuis and previously held the same position at the Slotervaartziekenhuis. He has been a professor at the pharmaceutical faculty of Utrecht University since 1994.
Jos Beijnen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs (1994) (2237)
- Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. (1997) (898)
- The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria (2002) (817)
- A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent (2004) (676)
- Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. (2000) (660)
- Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. (2012) (577)
- An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. (2003) (550)
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies (2010) (544)
- A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. (2002) (513)
- Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. (1995) (499)
- Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not? (2005) (481)
- Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. (2000) (478)
- Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. (2002) (461)
- Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. (2012) (440)
- Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein (1997) (440)
- Clinical Pharmacokinetics of Cyclophosphamide (1979) (373)
- Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. (1993) (326)
- Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. (2006) (324)
- Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. (1996) (321)
- Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein (1996) (304)
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM (2011) (297)
- Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. (2011) (285)
- Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. (1997) (284)
- Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy (2015) (283)
- Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). (2007) (280)
- Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. (2013) (273)
- Characterization of the MRP4- and MRP5-mediated Transport of Cyclic Nucleotides from Intact Cells* (2003) (270)
- P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan (2007) (267)
- Taxanes: a new class of antitumor agents. (1995) (264)
- Development of farnesyl transferase inhibitors: a review. (2005) (262)
- Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)* (2001) (260)
- Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. (2001) (256)
- Drug interactions in oncology. (2004) (249)
- The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. (2003) (247)
- Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. (2014) (246)
- Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs (2002) (243)
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. (2015) (243)
- Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel (2001) (241)
- Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. (2003) (240)
- Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export (2000) (239)
- Breast cancer in pregnancy: recommendations of an international consensus meeting. (2010) (236)
- Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. (2007) (235)
- Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. (1998) (234)
- Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk (2006) (233)
- Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. (2016) (230)
- High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals (2001) (230)
- Herb-drug interactions in oncology: focus on mechanisms of induction. (2006) (227)
- Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles (2004) (227)
- Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. (2000) (214)
- Multidrug Resistance Protein 1 Protects the Oropharyngeal Mucosal Layer and the Testicular Tubules against Drug-induced Damage (1998) (208)
- An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential (2018) (208)
- Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. (2001) (208)
- Cyclodextrins in the Pharmaceutical Field (1991) (206)
- MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid (2005) (205)
- Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. (1999) (204)
- Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. (2005) (203)
- DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. (2018) (202)
- Antiretroviral drugs and the central nervous system. (1998) (202)
- Concise drug review: azacitidine and decitabine. (2013) (201)
- Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. (1997) (200)
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. (2016) (197)
- Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. (2006) (196)
- Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. (2001) (193)
- Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. (2002) (190)
- Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics. (2014) (190)
- Malignant effusions contain lysophosphatidic acid (LPA)-like activity. (1998) (188)
- Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. (1997) (183)
- Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice (2008) (183)
- Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. (1996) (181)
- Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets (2014) (180)
- Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? (2004) (178)
- A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors (2004) (175)
- Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment (2009) (173)
- Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations? (2005) (171)
- P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. (2001) (171)
- Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation (2010) (170)
- Drug interaction between St John's wort and nevirapine. (2001) (170)
- Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer (2011) (169)
- Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients (1999) (169)
- Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. (2002) (168)
- Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology (2017) (168)
- Clinical Pharmacokinetics of Topotecan (1996) (167)
- Drug Interactions Between Antiretroviral Drugs and Comedicated Agents (2003) (167)
- Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer (2006) (164)
- P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. (1999) (162)
- Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice (2006) (161)
- Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. (2006) (160)
- Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. (2008) (160)
- HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections (2002) (158)
- Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration (2012) (158)
- Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors (2019) (158)
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours (2012) (157)
- A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients (2007) (156)
- Oral Delivery of Taxanes (2001) (153)
- Relationship between cisplatin administration and the development of ototoxicity. (2006) (151)
- Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. (2006) (151)
- The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib (2009) (151)
- Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. (1998) (150)
- Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP (2012) (146)
- Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients (2008) (146)
- Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein (1999) (144)
- Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. (2002) (143)
- Modulation of oral bioavailability of anticancer drugs: from mouse to man. (2000) (143)
- The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals (2000) (141)
- Preclinical pharmacokinetics of paclitaxel and docetaxel. (1998) (141)
- Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review (2014) (138)
- The functional role of P-glycoprotein in the blood-brain barrier. (1997) (138)
- Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. (1999) (138)
- Aspects of the degradation kinetics of doxorubicin in aqueous solution (1986) (137)
- Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients (2001) (136)
- Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. (1996) (136)
- The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy (1998) (134)
- Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar (2014) (133)
- Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. (2000) (131)
- Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. (2002) (130)
- Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. (1996) (127)
- Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab (2009) (126)
- Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide (2008) (125)
- The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. (2005) (125)
- Co-administration of cyclosporin enables oral therapy with paclitaxel (1998) (125)
- Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel (2006) (124)
- Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. (2008) (123)
- The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. (2007) (122)
- The pharmacological role of P-glycoprotein in the intestinal epithelium. (1998) (122)
- Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. (1993) (121)
- Blood–brain barrier and chemotherapeutic treatment of brain tumors (2006) (121)
- Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. (1999) (120)
- Tissue distribution, metabolism and excretion of paclitaxel in mice (1996) (119)
- Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes (2008) (119)
- Liposomal drug formulations in the treatment of rheumatoid arthritis. (2011) (118)
- Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). (2005) (118)
- Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications (2000) (117)
- The biological and clinical role of drug transporters at the intestinal barrier. (2009) (117)
- Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin (2002) (116)
- Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. (2008) (116)
- Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses (2015) (116)
- Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study (2005) (115)
- Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. (2002) (115)
- High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. (1993) (114)
- Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. (2004) (113)
- Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. (2002) (113)
- Paclitaxel (Taxol) concentrations in brain tumor tissue. (1994) (112)
- The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. (1999) (112)
- Transplacental Transfer of Paclitaxel, Docetaxel, Carboplatin, and Trastuzumab in a Baboon Model (2010) (111)
- Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting (2009) (111)
- Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites (2001) (111)
- Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry (1994) (110)
- Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population (2003) (110)
- Reasons for Undertreatment with Oral Anticoagulants in Frail Geriatric Outpatients with Atrial Fibrillation (2010) (109)
- Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. (2012) (108)
- High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. (1990) (107)
- Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement (2013) (107)
- Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. (2010) (106)
- Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides (2007) (106)
- Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group (2007) (105)
- A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin (2002) (105)
- Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs (2004) (104)
- The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models (2007) (104)
- PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line (2009) (104)
- ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy (2014) (103)
- Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients (2007) (103)
- Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. (2014) (101)
- Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors (2006) (100)
- Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation (2005) (100)
- Clinical experience with aurora kinase inhibitors: a review. (2009) (100)
- Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. (2006) (99)
- The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. (2000) (98)
- Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA). (2000) (98)
- Fixed Dosing of Monoclonal Antibodies in Oncology (2017) (98)
- Drug-Drug Interactions in a Geriatric Outpatient Cohort (2008) (98)
- Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes (2001) (96)
- Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. (1998) (95)
- Variability in bioavailability of small molecular tyrosine kinase inhibitors. (2015) (94)
- Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics (2006) (94)
- Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). (2011) (93)
- Future opportunities in preventing cisplatin induced ototoxicity. (2006) (93)
- Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. (2006) (93)
- Long-term platinum retention after treatment with cisplatin and oxaliplatin (2008) (93)
- A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. (2002) (92)
- Alternative formulations of paclitaxel. (1997) (91)
- The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice (2004) (91)
- DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. (2003) (91)
- An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. (2009) (90)
- Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. (2006) (89)
- Clinical proteomics in breast cancer: a review (2009) (89)
- Persistent neuropathy after treatment with cisplatin and oxaliplatin (2009) (89)
- Phase I and pharmacokinetic study of oral paclitaxel. (2000) (89)
- Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. (2008) (87)
- Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. (2010) (87)
- Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity (2017) (87)
- Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. (2009) (86)
- New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine (2008) (86)
- Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor (2009) (86)
- Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines (2004) (85)
- Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liq (2007) (84)
- Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. (2003) (84)
- Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care (2014) (84)
- Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. (2006) (84)
- Therapeutic drug monitoring in cancer--are we missing a trick? (2014) (83)
- Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. (1990) (83)
- The Effects of Fall-Risk-Increasing Drugs on Postural Control: A Literature Review (2013) (82)
- HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53 (2015) (82)
- Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. (2011) (82)
- P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy (2004) (81)
- The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. (2008) (81)
- Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides (2008) (80)
- Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. (1998) (80)
- Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice (2004) (80)
- Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. (2006) (80)
- Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver (2000) (80)
- Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. (2019) (80)
- High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. (1995) (79)
- Ras biochemistry and farnesyl transferase inhibitors: a literature survey (2001) (79)
- Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors (2002) (79)
- P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide (2009) (78)
- Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours (2014) (78)
- Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone (2009) (78)
- Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. (1997) (77)
- Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093) (2004) (77)
- Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. (2003) (77)
- Pharmacokinetic interaction between rifampin and zidovudine (1993) (77)
- Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. (2014) (77)
- Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) (2014) (76)
- Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study (2011) (76)
- Mass Balance Studies, with a Focus on Anticancer Drugs (2006) (76)
- Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? (2016) (76)
- Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis (2012) (76)
- P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel (2013) (76)
- Concise drug review: pazopanib and axitinib. (2012) (76)
- Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters (2010) (75)
- Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. (2010) (75)
- Optimization of intradermal vaccination by DNA tattooing in human skin. (2008) (75)
- Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces. (1999) (75)
- Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. (1998) (74)
- Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. (2013) (74)
- Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. (2013) (73)
- Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. (2006) (73)
- Ritonavir enables combined therapy with rifampin and saquinavir. (1999) (73)
- Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. (2000) (73)
- DNA-based drug interactions of cisplatin. (2002) (73)
- Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. (2008) (72)
- Cisplatin resistance and DNA repair. (1997) (72)
- Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer (2005) (72)
- The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients (2001) (72)
- Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. (2000) (71)
- Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. (1995) (71)
- Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer (1999) (71)
- A flexed posture in elderly patients is associated with impairments in postural control during walking. (2014) (70)
- P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration (2011) (70)
- Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry (1995) (70)
- Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application (2005) (70)
- Isolation, purification and biological activity of major docetaxel metabolites from human feces. (1996) (70)
- Incidence and risk factors for nevirapine-associated rash (2003) (69)
- Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. (2016) (69)
- Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. (2009) (69)
- Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion (2000) (69)
- Pharmaceutical development of anticancer agents derived from marine sources (2000) (69)
- PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer (2018) (69)
- Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics (2011) (69)
- Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV (1993) (69)
- Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study (2008) (68)
- Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. (1995) (68)
- Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions. (2009) (68)
- Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. (2013) (68)
- The use of combinations of monoclonal antibodies in clinical oncology. (2015) (68)
- Heroin-assisted treatment in the Netherlands: History, findings, and international context (2010) (68)
- Population Pharmacokinetics of Heroin and its Major Metabolites (2006) (68)
- Lapatinib for advanced or metastatic breast cancer. (2012) (67)
- Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. (1998) (67)
- Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. (2005) (67)
- The Plasma and Intracellular Steady-State Pharmacokinetics of Lopinavir/Ritonavir in HIV-1-Infected Patients (2004) (67)
- Cardiometabolic risk variables in overweight and obese children: a worldwide comparison (2011) (66)
- P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin (2007) (66)
- Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. (2008) (65)
- Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. (2010) (65)
- Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam (2009) (65)
- Oral topotecan: bioavailability and effect of food co-administration (1999) (65)
- Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option (2014) (64)
- Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors (2009) (64)
- Pharmacokinetically Guided Administration of Chemotherapeutic Agents (2000) (64)
- Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients (2016) (63)
- Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. (2013) (63)
- Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. (1995) (63)
- Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study (2008) (63)
- Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG21 (2018) (63)
- Inhibitors of mTOR. (2010) (63)
- A Pharmacokinetic and Pharmacogenetic Study of Efavirenz in Children: Dosing Guidelines can Result in Subtherapeutic Concentrations (2008) (63)
- Analytical techniques used to study the degradation of proteins and peptides: physical instability. (1998) (63)
- P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib (2015) (62)
- Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor-Mediated CYP3A4 Induction (2008) (62)
- The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. (2001) (62)
- Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. (2006) (62)
- Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. (1999) (62)
- Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy (2012) (61)
- Application of PET/CT in the development of novel anticancer drugs. (2008) (61)
- Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism (2005) (61)
- Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. (1995) (61)
- High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva. (1998) (60)
- High-grade glioma mouse models and their applicability for preclinical testing. (2009) (60)
- Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. (2014) (60)
- Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. (2011) (59)
- Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV‐care (2004) (59)
- Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. (1997) (59)
- Simplifying Protease Inhibitor Therapy with Once‐Daily Dosing of Saquinavir Soft‐Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 Study (2002) (59)
- Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). (2015) (59)
- Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam (2005) (58)
- Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. (1999) (58)
- DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update (2017) (58)
- Assessing Safety and Efficacy of Directed P-Glycoprotein Inhibition to Improve the Pharmacokinetic Properties of Saquinavir Coadministered with Ritonavir (2003) (57)
- Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. (2005) (57)
- Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples (2017) (57)
- Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. (2011) (56)
- Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut (2002) (56)
- Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. (2002) (56)
- Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. (2003) (56)
- Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer (2003) (56)
- A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. (2009) (56)
- Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations (2007) (56)
- Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. (2003) (56)
- A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A. (2002) (56)
- Ifosfamide metabolism and pharmacokinetics (review). (1994) (56)
- Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. (2015) (56)
- Analytical techniques used to study the degradation of proteins and peptides: chemical instability. (1998) (55)
- Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods (2000) (55)
- The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel (2013) (55)
- A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. (2019) (55)
- Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (2004) (55)
- Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review). (1992) (54)
- Population Pharmacokinetics and Pharmacodynamics of Mitomycin During Intraoperative Hyperthermic Intraperitoneal Chemotherapy (2004) (54)
- Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (2004) (54)
- Drug interactions with zidovudine. (1993) (54)
- An overview of the clinical pharmacology of topotecan. (1997) (54)
- Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. (2006) (54)
- Symptoms and treatment in cancer therapy-induced early menopause. (2006) (54)
- Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing (2017) (54)
- Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. (2006) (54)
- Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir (1997) (54)
- Complement activation by PEGylated liposomes containing prednisolone. (2013) (54)
- Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. (2007) (53)
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 (2010) (53)
- Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study (2009) (53)
- High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients. (1995) (53)
- Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? (2009) (53)
- Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen (2015) (53)
- Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks (1995) (53)
- Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis (2014) (53)
- Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D (2009) (53)
- Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin (2008) (52)
- Clinical pharmacology of anticancer agents in relation to formulations and administration routes. (1999) (52)
- Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. (2002) (52)
- Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. (2012) (52)
- Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. (2009) (52)
- Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs (2017) (52)
- Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs. (2005) (52)
- Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry. (2006) (51)
- Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function (2006) (51)
- Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. (1994) (51)
- Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) (2015) (51)
- In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. (1998) (51)
- Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG) (1999) (51)
- Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. (2011) (51)
- Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. (2006) (51)
- Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors (2009) (51)
- 32P-postlabeling assay for the quantification of the major platinum-DNA adducts. (1999) (51)
- Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. (1997) (51)
- Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel (1997) (50)
- Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. (1997) (50)
- Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (1998) (50)
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer (2007) (50)
- Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis. (2011) (50)
- Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. (2009) (50)
- Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens (2000) (50)
- Effect of Chinese herbs on CYP3A4 activity and expression in vitro. (2013) (50)
- Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. (2010) (50)
- Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. (2006) (50)
- ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2‐Inhibitors (2015) (50)
- Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies (2010) (49)
- Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes. (2012) (49)
- Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. (2002) (49)
- Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. (2003) (49)
- Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV‐1 infected individuals (1998) (49)
- Individual and combined roles of CYP3A, P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel (2010) (49)
- High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. (1995) (49)
- Intravenous‐to‐Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel (2010) (49)
- Taxanes: old drugs, new oral formulations. (2013) (49)
- Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. (2014) (49)
- Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma (2005) (49)
- PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models (2016) (48)
- Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up (2020) (48)
- Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study (2002) (48)
- Survival after massive ecstasy overdose. (1998) (48)
- Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib (2013) (48)
- Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors (2007) (48)
- Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data (2008) (48)
- The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery (2000) (48)
- Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces (1995) (48)
- Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel (2015) (48)
- Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. (2000) (48)
- The impact of P‐glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors (2018) (47)
- MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4 (2005) (47)
- Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas (2015) (47)
- Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors (2011) (47)
- Quantitative determination of (-)-2'-deoxy-3'-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection. (1998) (47)
- Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6 (2007) (46)
- BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. (2017) (46)
- Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection. (1997) (46)
- Clinical research on antiangiogenic therapy. (1998) (46)
- Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. (2009) (46)
- Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. (2008) (46)
- Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). (2007) (46)
- Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine (2019) (46)
- Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals. (2002) (46)
- GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. (2008) (46)
- Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry (2007) (45)
- A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. (2011) (45)
- A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. (2006) (45)
- Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method. (2009) (45)
- Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues (2013) (45)
- Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. (2009) (45)
- Pharmacokinetic variability of zidovudine in HIV‐infected individuals: subgroup analysis and drug interactions (1994) (45)
- Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer (2004) (45)
- Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. (1996) (45)
- Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review. (2010) (45)
- Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin (2008) (45)
- Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study (2000) (45)
- Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response (2014) (44)
- Inclusion complexation of doxorubicin and daunorubicin with cyclodextrins. (1990) (44)
- Anthracycline antitumour agents (1986) (44)
- Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry (2007) (44)
- Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. (2007) (44)
- Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry. (2002) (44)
- Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. (1999) (44)
- Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. (2010) (44)
- Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. (2002) (43)
- Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK (2015) (43)
- Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes (2019) (43)
- Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (2017) (43)
- Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care (2014) (43)
- A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer (2006) (43)
- EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. (2016) (43)
- Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules (1996) (42)
- Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer (2015) (42)
- Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin (2002) (42)
- Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan (1997) (42)
- A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide (2001) (42)
- Breast cancer resistance protein (BCRP/ABCG2) and P‐glycoprotein (P‐gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation☆ (2017) (42)
- P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib (2012) (42)
- The analysis of ifosfamide and its metabolites (review). (1993) (41)
- Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. (2007) (41)
- Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. (2006) (41)
- PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors. (2013) (41)
- A Bead-Based Multiplexed Immunoassay to Evaluate Breast Cancer Biomarkers for Early Detection in Pre-Diagnostic Serum (2012) (41)
- A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. (1992) (41)
- HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients. (1991) (41)
- Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. (1996) (41)
- Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. (2016) (41)
- Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance. (2004) (40)
- Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation (2014) (40)
- Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. (2016) (40)
- Ethnic differences in cardiometabolic risk profile in an overweight/obese paediatric cohort in the Netherlands: a cross-sectional study (2009) (40)
- Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples (2003) (40)
- Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. (2018) (40)
- In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug (2006) (39)
- Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. (2011) (39)
- Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure (1996) (39)
- Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. (2004) (39)
- Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. (2005) (39)
- Buparlisib is a brain penetrable pan-PI3K inhibitor (2018) (39)
- Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology (2008) (39)
- Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment (2012) (39)
- Hepatotoxicity and metabolism of trabectedin: a literature review. (2005) (39)
- Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin (1995) (39)
- Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. (2013) (38)
- Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review (1996) (38)
- P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo (2003) (38)
- Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. (2002) (38)
- Hypersensitivity Reactions to Etoposide (1996) (38)
- Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors (2008) (38)
- Clinical pharmacology of carboplatin administered in combination with paclitaxel. (1997) (38)
- Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. (2005) (38)
- The G2 checkpoint—a node‐based molecular switch (2017) (38)
- Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. (2009) (38)
- Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). (1994) (38)
- Modulation of the cytochrome P450–mediated metabolism of ifosfamide by ketoconazole and rifampin (2001) (38)
- Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. (2001) (37)
- In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction (2005) (37)
- O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. (1998) (37)
- Serum degradome markers for the detection of breast cancer. (2010) (37)
- Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. (2013) (37)
- Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment (2003) (37)
- Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin (2005) (37)
- The use of the Calvert formula to determine the optimal carboplatin dosage (2005) (37)
- Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. (2007) (36)
- Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. (2016) (36)
- Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. (2013) (36)
- A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal (2012) (36)
- P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. (2013) (36)
- Stable and sensitive method for the simultaneous determination of N5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids. (1989) (35)
- Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry. (2009) (35)
- Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. (2016) (35)
- Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry (2016) (35)
- Degradation of mitomycin C in acidic solution (1985) (35)
- Characterization and identification of suspected counterfeit miltefosine capsules. (2012) (35)
- Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring (2012) (35)
- The absolute quantification of eight inter‐α‐trypsin inhibitor heavy chain 4 (ITIH4)‐derived peptides in serum from breast cancer patients (2010) (34)
- Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid (2019) (34)
- Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. (1992) (34)
- Gait dynamics to optimize fall risk assessment in geriatric patients admitted to an outpatient diagnostic clinic (2017) (34)
- Part 1: background, methodology, and clinical adoption of pharmacogenetics. (2011) (34)
- In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2 (2007) (34)
- Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology (2018) (34)
- E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. (2002) (34)
- Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. (1995) (34)
- Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry (2019) (34)
- Pharmacokinetics and Excretion of 14C-Bendamustine in Patients with Relapsed or Refractory Malignancy (2013) (34)
- Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. (2013) (34)
- The association of elevated alanine aminotransferase and the metabolic syndrome in an overweight and obese pediatric population of multi-ethnic origin (2009) (34)
- Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. (2007) (34)
- Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. (2016) (33)
- Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen (2014) (33)
- Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen (2012) (33)
- Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. (1999) (33)
- Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F (2001) (33)
- Detection of Single Nucleotide Polymorphisms in theABCG2Gene in a Dutch Population (2005) (33)
- Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. (2009) (33)
- CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis (2011) (33)
- CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis (2011) (33)
- A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer (2004) (33)
- Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. (2016) (33)
- Limited Sampling Strategies for the Estimation of the Systemic Exposure to the HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Nevirapine (2001) (32)
- Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. (2012) (32)
- Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients (2007) (32)
- Synthetic vehicles for DNA vaccination (2009) (32)
- The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel (2001) (32)
- Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients (2017) (32)
- Effect of Mycophenolate Mofetil on the Pharmacokinetics of Antiretroviral Drugs and on Intracellular Nucleoside Triphosphate Pools (2004) (32)
- The effect of complementary and alternative medicines on CYP3A4‐mediated metabolism of three different substrates: 7‐benzyloxy‐4‐trifluoromethyl‐coumarin, midazolam and docetaxel (2014) (32)
- Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. (1999) (32)
- Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours (2005) (32)
- Limited-sampling models for anticancer agents (2005) (32)
- Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. (2016) (32)
- Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. (2011) (32)
- Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study (2016) (32)
- Subtherapeutic Antiretroviral Plasma Concentrations in Routine Clinical Outpatient HIV Care (2003) (32)
- Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine (2011) (32)
- Mitomycin antitumour agents: a review of their physico-chemical and analytical properties and stability. (1986) (32)
- P‐glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice (2017) (31)
- Aspects of the chemical stability of doxorubicin and seven other anthracydines in acidic solution (1985) (31)
- A phase I and pharmacokinetic study of intraperitoneal topotecan (2001) (31)
- Degradation kinetics of etoposide in aqueous solution (1988) (31)
- Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study (2016) (31)
- Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism. (2011) (31)
- Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. (2012) (31)
- Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. (2010) (31)
- Population pharmacokinetics of the novel anticancer agent KRN7000 (2002) (31)
- Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. (2002) (31)
- Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. (2011) (31)
- Allometric scaling of pegylated liposomal anticancer drugs (2011) (31)
- Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer (2016) (31)
- Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. (1998) (31)
- Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry (2000) (31)
- The performance of model-based versus rule-based phase I clinical trials in oncology (2016) (30)
- CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity (2007) (30)
- Milk Thistle’s Active Components Silybin and Isosilybin: Novel Inhibitors of PXR-Mediated CYP3A4 Induction (2013) (30)
- Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling. (2019) (30)
- Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer (2007) (30)
- Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole (2013) (30)
- Synthesis, radiolabelling and stability of radioiodinated m-iodobenzylguanidine, a review. (1994) (30)
- Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site (2020) (30)
- Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection. (2001) (30)
- The risks of handling cytotoxic drugs (1990) (30)
- Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses (2012) (30)
- Extensive Metabolism and Hepatic Accumulation of Gemcitabine After Multiple Oral and Intravenous Administration in Mice (2008) (30)
- Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review (2019) (30)
- Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. (2010) (30)
- Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. (1993) (30)
- Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. (2011) (30)
- Screening for polymorphisms in the PXR gene in a Dutch population (2006) (30)
- Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. (2011) (29)
- Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS) (2009) (29)
- Saliva as an Alternative Body Fluid for Therapeutic Drug Monitoring of the Nonnucleoside Reverse Transcription Inhibitor Nevirapine (2001) (29)
- Identification of the degradation products of gonadorelin and three analogues in aqueous solution (1997) (29)
- Effects of Lycopene on the Insulin-Like Growth Factor (IGF) System in Premenopausal Breast Cancer Survivors and Women at High Familial Breast Cancer Risk (2008) (29)
- A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry. (2004) (29)
- Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis (2019) (29)
- Urinary and fecal excretion of topotecan in patients with malignant solid tumours (2002) (29)
- Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. (2016) (29)
- Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. (2016) (29)
- Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. (2012) (29)
- Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. (2008) (28)
- Changes in Under-Treatment after Comprehensive Geriatric Assessment (2010) (28)
- HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE STABILIZED CYCLOPHOSPHAMIDE METABOLITE 4-HYDROXYCYCLOPHOSPHAMIDE IN PLASMA AND RED BLOOD CELLS (2000) (28)
- Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours (2005) (28)
- Erlotinib and pantoprazole: a relevant interaction or not? (2010) (28)
- Severe encephalopathy and polyneuropathy induced by dichloroacetate (2010) (28)
- High prevalence of vitamin D insufficiency/deficiency in Dutch multi-ethnic obese children (2015) (28)
- Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer (2006) (28)
- Steady‐State Pharmacokinetics of Twice‐Daily Dosing of Saquinavir Plus Ritonavir in HIV‐1‐Infected Individuals (2001) (28)
- Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity (2016) (28)
- Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases (2020) (28)
- A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). (2003) (28)
- Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin (2005) (28)
- Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man (2001) (28)
- Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. (2012) (28)
- Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine. (2000) (28)
- Evaluation of Pharmacotherapy in Geriatric Patients after Performing Complete Geriatric Assessment at a Diagnostic Day Clinic (2006) (28)
- Etoposide phosphate, the water soluble prodrug of etoposide (1996) (28)
- Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers (2006) (28)
- Proteomics in uveal melanoma (2003) (28)
- Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals (2005) (28)
- Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study (2005) (28)
- Therapeutic Drug Monitoring of Antiretroviral Drugs at Home Using Dried Blood Spots: A Proof-Of-Concept Study (2013) (28)
- Naked Plasmid DNA Formulation: Effect of Different Disaccharides on Stability after Lyophilisation (2010) (27)
- Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome. (1994) (27)
- Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects. (2014) (27)
- Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies (2011) (27)
- Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. (2015) (27)
- Intermittent fasting during Ramadan causes a transient increase in total, LDL, and HDL cholesterols and hs-CRP in ethnic obese adolescents (2014) (27)
- The Association of Medication-Use and Frailty-Related Factors with Gait Performance in Older Patients (2016) (27)
- DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms. (2009) (27)
- Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. (2008) (27)
- P‐glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450‐3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib (2018) (27)
- High-Performance Liquid Chromatographic Analysis of the Anticancer Drug Irinotecan (CPT-11) and Its Active Metabolite SN-38 in Human Plasma (2003) (27)
- Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma. (2019) (27)
- Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. (1998) (27)
- Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. (2010) (27)
- Slow dissolution behaviour of amorphous capecitabine. (2013) (27)
- Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography. (2000) (27)
- Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib (2020) (27)
- Capecitabine induces severe angina-like chest pain. (2004) (27)
- Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2 (2013) (27)
- Influence of variations in sample handling on SELDI‐TOF MS serum protein profiles for colorectal cancer (2008) (27)
- Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. (1998) (27)
- Mass Balance Study of [14C]Eribulin in Patients with Advanced Solid Tumors (2012) (26)
- Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. (2011) (26)
- Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine (2011) (26)
- Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients (2008) (26)
- Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options? (2020) (26)
- Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. (2011) (26)
- Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. (2002) (26)
- Penetration of Idarubicin into Malignant Brain Tumor Tissue (1999) (26)
- The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum. (2009) (26)
- Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors (2007) (26)
- EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid (2018) (26)
- Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. (2012) (26)
- Integrated Population Pharmacokinetic Model of Both Cyclophosphamide and Thiotepa Suggesting a Mutual Drug–Drug Interaction (2004) (26)
- Morphine Induces Hyperalgesia without Involvement of µ-Opioid Receptor or Morphine-3-glucuronide (2012) (26)
- Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. (2010) (26)
- Early diagnostic protein biomarkers for breast cancer: how far have we come? (2012) (26)
- Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. (2007) (26)
- Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. (2016) (26)
- Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer (2020) (26)
- Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure (2001) (25)
- A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. (2006) (25)
- The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. (2013) (25)
- Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. (2006) (25)
- Improving the solubility of nilotinib through novel spray-dried solid dispersions. (2017) (25)
- Influence of Cremophor EL on the quantification of paclitaxel in plasma using high-performance liquid chromatography with solid-phase extraction as sample pretreatment. (1998) (25)
- Limited sampling models for topotecan pharmacokinetics. (1994) (25)
- Optimizing drug development of anti‐cancer drugs in children using modelling and simulation (2013) (25)
- Renal excretion of iodine-131 labelledmeta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours (1997) (25)
- Development of a Lyophilized Parenteral Pharmaceutical Formulation of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F (2001) (25)
- Increased risk of severe fluoropyrimidine‐associated toxicity in patients carrying a G to C substitution in the first 28‐bp tandem repeat of the thymidylate synthase 2R allele (2016) (25)
- Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma – drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study (1999) (25)
- Pharmacokinetic Individualisation of Zidovudine Therapy (1996) (25)
- Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice (2010) (25)
- Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma. (2013) (25)
- Inclusion complex formation of anthracycline antibiotics with cyclodextrins; a proton nuclear magnetic resonance and molecular modelling study (1991) (25)
- A search for new metabolites of N,N',N''-triethylenethiophosphoramide. (1999) (25)
- Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma (2017) (24)
- Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). (2019) (24)
- Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. (2006) (24)
- Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. (1994) (24)
- Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. (2009) (24)
- Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). (2009) (24)
- steady-state Pharmacokinetics of Twice-daily Dosing of Saquinavir Plus Ritonavir in Hiv-1-infected Individuals (2001) (24)
- P-Glycoprotein, Multidrug-Resistance Associated Protein 2, Cyp3a, and Carboxylesterase Affect the Oral Availability and Metabolism of Vinorelbine (2012) (24)
- Ciprofloxacin Strongly Inhibits Clozapine Metabolism (2009) (24)
- High Concentration of Daunorubicin and Daunorubicinol in Human Malignant Astrocytomas after Systemic Administration of Liposomal Daunorubicin (2001) (24)
- Clinically relevant drug interactions with antiretroviral agents. (1997) (24)
- P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. (2019) (24)
- Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry. (2018) (24)
- P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice (2014) (24)
- Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular‐signal‐regulated kinase and DNA in circulating tumor cells (2012) (24)
- Identification of responders and reactive domains to rivastigmine in Alzheimer's disease (2007) (23)
- Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies (2010) (23)
- Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). (2005) (23)
- Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration (2000) (23)
- Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA (2013) (23)
- The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients (2016) (23)
- Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation (2019) (23)
- Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. (2012) (23)
- Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. (1991) (23)
- Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. (2013) (23)
- Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction. (1998) (23)
- Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. (2015) (23)
- P‐glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability (2018) (23)
- Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. (2005) (23)
- Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820 (2009) (22)
- Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. (2014) (22)
- RT-PCR detection of respiratory pathogens in newborn children admitted to a neonatal medium care unit (2012) (22)
- Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model (2016) (22)
- Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients (2017) (22)
- HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier. (1997) (22)
- Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients? (2000) (22)
- Oxidation of recombinant methionyl human granulocyte colony stimulating factor. (1998) (22)
- Therapeutic drug monitoring of non-anticancer drugs in cancer patients. (2004) (22)
- Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study (2022) (22)
- Bcrp1;Mdr1a/b;Mrp2 Combination Knockout Mice: Altered Disposition of the Dietary Carcinogen PhIP (2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine) and Its Genotoxic Metabolites (2014) (22)
- Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers (2018) (22)
- Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. (2012) (22)
- Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties (2005) (22)
- Reduced Liver Uptake of Arterially Infused Melphalan during Retrograde Rat Liver Perfusion with Unaffected Liver Tumor Uptake (2002) (22)
- Cytostatic drugs in infants: a review on pharmacokinetic data in infants. (2012) (22)
- Discrepancies between Medical and Pharmacy Records for Patients on Anti-HIV Drugs (2002) (22)
- Crizotinib-induced fatal fulminant liver failure. (2016) (21)
- Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (2012) (21)
- Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. (2005) (21)
- In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug (2007) (21)
- The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. (2001) (21)
- Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent. (2005) (21)
- Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′‐difluorodeoxyuridine and their nucleotides (2018) (21)
- Degradation study of thiotepa in aqueous solutions. (1999) (21)
- Limited sampling model for area under the concentration time curve of total topotecan. (1996) (21)
- Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies (2016) (21)
- ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost (2021) (21)
- Stability of anthracycline antitumour agents in infusion fluids. (1985) (21)
- Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde. (1999) (21)
- Process characterisation, optimisation and validation of production of diacetylmorphine/caffeine sachets: a design of experiments approach. (2004) (21)
- Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma? (2013) (21)
- Determination of Ifosfamide, 2- and 3-Dechloroethyifosfamide Using Gas Chromatography With Nitrogen-Phosphorus or Mass Spectrometry Detection (2000) (21)
- Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature. (1991) (21)
- A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. (2017) (21)
- Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). (2017) (20)
- In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS. (2000) (20)
- Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors (2010) (20)
- Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment (2016) (20)
- Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (2013) (20)
- Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry (2005) (20)
- Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (2005) (20)
- Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose (2018) (20)
- Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. (2007) (20)
- Increasing thyroid-stimulating hormone is associated with impaired glucose metabolism in euthyroid obese children and adolescents (2013) (20)
- Stability of intravenous admixtures of doxorubicin and vincristine. (1986) (20)
- Pharmacokinetics of ifosfamide and some metabolites in children. (1998) (20)
- Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review (2016) (20)
- Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection. (1992) (20)
- CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs. (1995) (20)
- Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. (2014) (20)
- Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration. (1999) (20)
- Quantification of Sunitinib and N-Desethyl Sunitinib in Human EDTA Plasma by Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry: Validation and Application in Routine Therapeutic Drug Monitoring (2013) (20)
- Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples. (2010) (20)
- Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. (2014) (20)
- Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. (1996) (20)
- Pharmacokinetics of sunitinib in an obese patient with a GIST. (2008) (20)
- Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. (1994) (20)
- Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry. (2009) (20)
- A general approach to the interpretation of pH degradation profiles (1988) (20)
- Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. (2011) (20)
- A systematic study on the chemical stability of the novel indoloquinone antitumour agent EO9 (1993) (20)
- Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. (2007) (20)
- Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin (2013) (19)
- Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. (2010) (19)
- Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. (2019) (19)
- Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting (2006) (19)
- Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and 11C-Erlotinib PET (2017) (19)
- High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine. (1995) (19)
- Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel (2001) (19)
- Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A. (2003) (19)
- The Pharmacokinetics of Nelfinavir in HIV-1—Infected Children (2002) (19)
- ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients (2006) (19)
- The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography–inductively coupled plasma mass spectrometry (2008) (19)
- High-performance liquid chromatographic analysis of the antitumour drug camptothecin and its lactone ring-opened form in rat plasma. (1993) (19)
- Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours (2007) (19)
- Model-based treatment optimization of a novel VEGFR inhibitor. (2012) (19)
- Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. (2015) (19)
- RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics (2020) (19)
- Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. (2008) (19)
- [Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute]. (1999) (19)
- Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. (2012) (19)
- Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. (2013) (19)
- Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. (2012) (19)
- Determination of pamidronate in urine by ion-pair liquid chromatography after derivatization with 1-naphthylisothiocyanate. (1997) (19)
- Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer (2017) (19)
- Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule (2002) (19)
- Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A. (2002) (19)
- Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer (2005) (19)
- Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial (2017) (19)
- [Concomitant use of proton pump inhibitors and systemic corticosteroids]. (2013) (19)
- Semi-automatic liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chloroformate. (2000) (19)
- Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. (1996) (19)
- Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction (2015) (18)
- Metabolism of docetaxel in mice (2005) (18)
- Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. (2005) (18)
- Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel (2001) (18)
- Capillary zone electrophoresis–mass spectrometry as a tool in the stability research of the luteinising hormone-releasing hormone analogue goserelin (1997) (18)
- Degradation kinetics of gonadorelin in aqueous solution. (1996) (18)
- Limited value of routine microalbuminuria assessment in multi-ethnic obese children (2013) (18)
- Discontinuation of rivastigmine in routine clinical practice (2005) (18)
- Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites (2013) (18)
- Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy (2014) (18)
- Baclofen overdose treated with continuous venovenous hemofiltration (2015) (18)
- Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry (2002) (18)
- Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. (2005) (18)
- Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. (2010) (18)
- Population Pharmacokinetics of Ifosfamide and its Dechloroethylated and Hydroxylated Metabolites in Children with Malignant Disease (2001) (18)
- Monitoring Carboplatin Concentrations in Saliva: A Replacement for Plasma Ultrafiltrate Measurements? (1995) (18)
- Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. (2005) (18)
- Cyclosporine-Induced Anaphylaxis (2000) (18)
- Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. (2016) (18)
- The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. (2012) (18)
- Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals (2003) (18)
- An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome (2017) (18)
- Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients (2020) (18)
- A real or apparent decrease in glomerular filtration rate in patients using olaparib? (2020) (18)
- Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study (2012) (18)
- Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study (2017) (18)
- Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A. (2002) (18)
- Inherent formulation issues of kinase inhibitors. (2016) (18)
- Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. (1997) (17)
- Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma) (2000) (17)
- Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry. (2016) (17)
- High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes. (1998) (17)
- A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling (2002) (17)
- SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES (2006) (17)
- An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. (2011) (17)
- Study on didanosine concentrations in cerebrospinal fluid (1995) (17)
- Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. (2006) (17)
- Treatment Individualization in Colorectal Cancer (2015) (17)
- Can Fluconazole Concentrations in Saliva Be Used for Therapeutic Drug Monitoring? (2001) (17)
- Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle (2007) (17)
- Design of a drug‐drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation (2014) (17)
- In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug (2004) (17)
- Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue. (2012) (17)
- Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma. (2012) (17)
- Overweight children with type 1 diabetes have a more favourable lipid profile than overweight non-diabetic children (2011) (17)
- A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. (2008) (17)
- Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. (1997) (17)
- Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS. (2014) (17)
- A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy. (2009) (17)
- Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography. (1993) (17)
- P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. (2015) (17)
- Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids. (1992) (17)
- Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. (2015) (17)
- Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use. (1993) (17)
- Screening for illicit heroin use in patients in a heroin-assisted treatment program. (2006) (17)
- Protein versus DNA as a marker for peripheral blood mononuclear cell counting (2009) (16)
- Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate. (1999) (16)
- Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer (2008) (16)
- Genetically modified mouse models for oral drug absorption and disposition. (2013) (16)
- Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. (1999) (16)
- Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology (2003) (16)
- Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk (2008) (16)
- Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors (2012) (16)
- A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application (2006) (16)
- Bioanalytical liquid chromatography‐tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates (2018) (16)
- Bioanalysis of HIV protease inhibitors in samples from sanctuary sites. (2005) (16)
- Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison (2016) (16)
- Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. (2004) (16)
- Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer (2006) (16)
- EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs. (1988) (16)
- Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib (2019) (16)
- Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate. (1998) (16)
- Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection. (2004) (16)
- Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer (2020) (16)
- Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer. (2007) (16)
- Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. (2004) (16)
- Chromatographic determination of the radiochemical purity of [131I]MIBG infusion fluids: a comparison and discussion of the chromatographic characteristics using three different techniques (1993) (16)
- Stabilization of mitomycins on complexation with cyclodextrins in aqueous acidic media (1989) (16)
- Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. (2019) (16)
- Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis (2019) (16)
- Population Pharmacokinetics of Itraconazole in Thai HIV-1-Infected Persons (2003) (16)
- Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. (2014) (15)
- The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors (2004) (15)
- Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole. (1999) (15)
- Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. (2020) (15)
- Differential impact of impaired fasting glucose versus impaired glucose tolerance on cardiometabolic risk factors in multi-ethnic overweight/obese children (2010) (15)
- Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy. (2018) (15)
- Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography (1993) (15)
- Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype (2007) (15)
- Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. (2013) (15)
- Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies (2011) (15)
- A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen (1999) (15)
- Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection. (2001) (15)
- A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir (2019) (15)
- Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens (1998) (15)
- Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin. (2006) (15)
- Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant? (2010) (15)
- Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry. (2013) (15)
- Abstract 5687: Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer (2012) (15)
- A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam (2006) (15)
- High-performance liquid chromatographic determination of vinblastine, 4-O-deacetylvinblastine and the potential metabolite 4-O-deacetylvinblastine-3-oic acid in biological fluids. (1991) (15)
- Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines (2016) (15)
- Inducing synthetic lethality using PARP inhibitors. (2010) (15)
- Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans. (1996) (15)
- Sensitive Determination of the Carboxylate and Lactone Forms of the Novel Antitumor Drug Irinotecan and Its Active Metabolite in Plasma by HPLC (1998) (15)
- Structure elucidation and characterization of daunorubicin degradation products (1987) (15)
- The in‐vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity (2014) (15)
- Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry (2001) (15)
- Long term stability of lyophilized plasmid DNA pDERMATT. (2013) (15)
- Degradation kinetics of vinblastine sulphate in aqueous solutions (1988) (15)
- Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. (2014) (15)
- Qualitative aspects of the degradation of mitomycins in alkaline solution. (1985) (15)
- Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. (1989) (15)
- Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis (2018) (15)
- Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells. (2002) (15)
- Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population (2012) (15)
- Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment (2018) (15)
- Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection (2016) (15)
- Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study. (2005) (15)
- Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT. (2009) (15)
- Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. (1999) (15)
- Effect of cyclodextrin complexation on the chemical stability of doxorubicin and daunorubicin in aqueous solutions (1991) (15)
- Solubility and bioavailability improvement of pazopanib hydrochloride (2018) (15)
- Quantitative aspects of the degradation of mitomycin C in alkaline solution. (1985) (15)
- An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients (2002) (15)
- Metabolism of paclitaxel in mice (2003) (14)
- Predictive Value of Microdose Pharmacokinetics (2019) (14)
- Ultra‐sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine in human plasma for a microdose clinical trial (2018) (14)
- Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. (2011) (14)
- Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir. (2000) (14)
- Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. (2013) (14)
- A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours (2008) (14)
- SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. (2006) (14)
- Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. (2017) (14)
- Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. (2015) (14)
- Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. (2004) (14)
- ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461. (2018) (14)
- Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency (2008) (14)
- Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study. (2020) (14)
- Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. (2003) (14)
- A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A (2001) (14)
- Identifying the metabolic syndrome in obese children and adolescents: do age and definition matter? (2009) (14)
- Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces an (2010) (14)
- Limited Sampling Strategies for Investigating Paclitaxel Pharmacokinetics in Patients Receiving 175 mg/m2 as a 3-Hour Infusion (1995) (14)
- Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. (1996) (14)
- A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. (2005) (14)
- Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. (2016) (14)
- Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? (2011) (13)
- Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS). (2008) (13)
- Processing of Doxorubicin-Containing Liposomes by Liver Macrophages in Vitro (1989) (13)
- Derivatization of pamidronate and other amino(bis)phosphonates with different isothiocyanates prior to ion-pair liquid chromatography (1997) (13)
- Degradation of mitomycin C in acid phosphate and acetate buffer solutions (1986) (13)
- High-performance liquid chromatographic bioanalysis of anthracycline cytostatic drugs. (1988) (13)
- Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing. (2013) (13)
- The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma. (1996) (13)
- A rapid, simple and accurate method for the bioanalysis of zidovudine (1989) (13)
- Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer (2019) (13)
- Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. (2010) (13)
- Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients (2000) (13)
- Clinical Pharmacokinetics of Vemurafenib in BRAF‐Mutated Melanoma Patients (2017) (13)
- LC–MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide (2019) (13)
- Race Is Not Associated with Nevirapine Pharmacokinetics (2004) (13)
- The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry. (2009) (13)
- A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel (1999) (13)
- 2',3'-dideoxyinosine (ddI): its chemical stability and cyclodextrin complexation in aqueous media. (1993) (13)
- A systematic study on the chemical stability of ifosfamide. (1991) (13)
- Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. (2004) (13)
- Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen. (2000) (13)
- Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl. (2005) (13)
- Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors (2006) (13)
- Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents (2009) (13)
- Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes (2005) (13)
- Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique (2013) (13)
- Strategies to target drugs to gliomas and CNS metastases of solid tumors (2016) (13)
- High-performance liquid chromatography coupled with mass spectrometry for the quantitative analysis of vinca-alkaloids in biological matrices: a concise survey from the literature. (2010) (13)
- Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review). (1993) (13)
- Pharmacodynamic biomarkers in model-based drug development in oncology. (2011) (13)
- Compatibility and Stability of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F in Infusion Devices (2004) (13)
- Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. (2007) (13)
- Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer. (2006) (13)
- Herb–Drug Interactions in Oncology (2014) (13)
- Analysis of diacetylmorphine, caffeine, and degradation products after volatilization of pharmaceutical heroin for inhalation. (2006) (13)
- In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol. (2001) (13)
- Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. (2002) (12)
- LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. (2005) (12)
- Precision Dosing of Targeted Therapies Is Ready for Prime Time (2021) (12)
- Pharmacokinetic comparison of two methods of heroin smoking: ‘chasing the dragon’ versus the use of a heating device (2005) (12)
- Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography (2004) (12)
- Preparation and stability testing of a hydrogel for topical analgesia (1995) (12)
- Liquid chromatographic-mass spectrometric determination of the novel, recently identified thioTEPA metabolite, thioTEPA-mercapturate, in urine. (1999) (12)
- Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study (2017) (12)
- Effect of cyclodextrins on the chemical stability of mitomycins in alkaline solution. (1991) (12)
- Adult outpatient experience of the 2009 H1N1 pandemic: Clinical course, pathogens, and evaluation of case definitions (2011) (12)
- Commentary: Substandard medicines are the priority for neglected tropical diseases (2012) (12)
- Neoadjuvant Systemic Treatment of Primary Angiosarcoma (2020) (12)
- A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion (2001) (12)
- Development and Manufacture of Diacetylmorphine/Caffeine Sachets for Inhalation Via ‘Chasing the Dragon’ by Heroin Addicts (2004) (12)
- Population Pharmacokinetics and Pharmacodynamics of Nelfinavir and Its Active Metabolite M8 in HIV-1-Infected Children (2006) (12)
- Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin (2001) (12)
- The Pharmacokinetics of Topotecan and Its Carboxylate Form Following Separate Intravenous Administration to the Dog (1997) (12)
- Fast and Adequate Liquid Chromatography–Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring (2017) (12)
- Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort (2019) (12)
- Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. (2007) (12)
- Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. (2015) (12)
- Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS. (2014) (12)
- A systematic study on the chemical stability of mitomycin A and mitomycin B. (1986) (12)
- P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. (2018) (12)
- Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. (2020) (12)
- High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma. (2001) (12)
- Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen (2018) (12)
- Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. (2010) (12)
- Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients (2001) (12)
- Structural identification of the degradation products of the antitumor peptide antagonist [Arg6,D-Trp7,9,MePhe8]substance P (6-11). (1995) (12)
- Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study 1 (2000) (12)
- ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity (2009) (12)
- Metabolite Profiling of Bendamustine in Urine of Cancer Patients after Administration of [14C]Bendamustine (2012) (12)
- An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis. (2021) (12)
- Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. (2003) (12)
- Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. (1997) (12)
- Degradation kinetics of vincristine sulphate and vindesine sulphate in aqueous solutions (1989) (12)
- Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. (2009) (12)
- Systematic interpretation of pH-degradation profiles. A critical review (1997) (12)
- Determination of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of 3'-azido-3'-deoxythymidine, in human plasma by ion-pair high-performance liquid chromatography. (1993) (12)
- Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy. (2015) (11)
- Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands (2000) (11)
- In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood (2003) (11)
- Validation of a quantitative assay for human neutrophil peptide-1, -2, and -3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry. (2010) (11)
- Extrahepatic metabolism of ibrutinib (2020) (11)
- Carbamazepine induces bioactivation of cyclophosphamide and thiotepa (2009) (11)
- A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen. (2013) (11)
- Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: Case report and a review of the literature (2011) (11)
- Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study. (2015) (11)
- Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors. (2012) (11)
- A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study (1998) (11)
- Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD‐1 Expression Levels and PD‐1 Receptor Occupancy by Nivolumab and Pembrolizumab (2019) (11)
- The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice (2006) (11)
- Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature. (2009) (11)
- Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection. (2004) (11)
- Gas chromatographic determination of 2- and 3-dechloroethylifosfamide in plasma and urine. (1992) (11)
- OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation (2020) (11)
- Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer (2011) (11)
- Distribution of ifosfamide and metabolites between plasma and erythrocytes. (2001) (11)
- Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. (2018) (11)
- Gastric Bypass May Promote Weight Loss in Overweight Partners (2015) (11)
- The boosting of didanosine by allopurinol permits a halving of the didanosine dosage (2002) (11)
- Successful intraperitoneal suramin treatment of peritoneal mesothelioma. (1997) (11)
- Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). (2009) (11)
- Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort. (1994) (11)
- Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. (2006) (11)
- Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression (2009) (11)
- Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine. (2000) (10)
- Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Investigational Polymer-Conjugated Platinum Anticancer Agent AP 5280 (2003) (10)
- Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays. (2014) (10)
- Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine. (1997) (10)
- Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers (2010) (10)
- Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice (2010) (10)
- Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real‐world cohort study: does age matter? (2018) (10)
- Characterization of Absorption, Metabolism, and Elimination of Niraparib, an Investigational Poly (ADP-Ribose) Polymerase Inhibitor, in Cancer Patients (2017) (10)
- Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. (1999) (10)
- Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. (2022) (10)
- P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). (2019) (10)
- Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar (2017) (10)
- Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination (2013) (10)
- Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer. (1998) (10)
- Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors (2020) (10)
- Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. (1997) (10)
- Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. (2002) (10)
- Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination (2004) (10)
- Degradation Kinetics of Three Gonadorelin Analogues: Developing a Method for Calculating Epimerization Parameters (1998) (10)
- Radiochemical Purity, at Expiry, and Radiochemical Stability of Iodine-131 Labelled Meta-iodobenzylguanidine Concentrates for Intravenous Infusion (1996) (10)
- Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. (2020) (10)
- Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer (2015) (10)
- The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. (2021) (10)
- Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. (2018) (10)
- An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma. (2017) (10)
- A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma. (2011) (10)
- Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and response. (1994) (10)
- ET-743. Commentaries (2002) (9)
- Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy (2000) (9)
- Improving colorectal cancer management: the potential of proteomics. (2008) (9)
- Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. (2006) (9)
- Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. (2014) (9)
- Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152) (2011) (9)
- “Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183” (2014) (9)
- Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography. (1998) (9)
- Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. (2013) (9)
- Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. (2015) (9)
- Determination of 4-hydroxyifosfamide in biological matrices by high-performance liquid chromatography. (1997) (9)
- Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies (2017) (9)
- Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. (2013) (9)
- Facile Small Scale Synthesis of Nucleoside 5′-Phosphate Mixtures (2010) (9)
- Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction (2013) (9)
- Search for Breast Cancer Biomarkers in Fractionated Serum Samples by Protein Profiling With SELDI‐TOF MS (2012) (9)
- Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report. (2002) (9)
- Gas chromatographic analysis, with electron capture detection, of the antifungal drug fluconazole in microvolumes of human plasma. (1991) (9)
- Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS. (1995) (9)
- Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine. (1993) (9)
- A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development (2019) (9)
- Validation of a Therapeutic Drug Monitoring Strategy for Thiotepa in a High-Dose Chemotherapy Regimen (2001) (9)
- Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors. (2019) (9)
- Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method. (2019) (9)
- Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology. (2019) (9)
- The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers (2013) (9)
- Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. (2008) (9)
- Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab (2012) (9)
- The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry. (2009) (9)
- Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer. (2020) (9)
- Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. (2012) (9)
- Radiochemical purity of iodine-131 labelled metaiodobenzylguanidine infusion fluids: a report from clinical practice (1993) (9)
- Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. (2011) (9)
- Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure (2008) (9)
- Abstract 5537: GSH-conjugation improves efficacy of Doxil against intracranial xenografts (2010) (9)
- Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents (1995) (9)
- A general approach to the interpretation of pH buffer catalyzed degradation profiles (1994) (9)
- Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure–response relationships (2018) (8)
- Review on the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and its phase I and phase II metabolites in biological matrices, foodstuff and beverages. (2010) (8)
- Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. (2011) (8)
- Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1) (2019) (8)
- Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9 (2004) (8)
- Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action (2020) (8)
- Reversed-phase high-performance liquid chromatography and capillary electrophoresis in the stability study of the neuropeptide growth factor antagonist [Arg6,D-Trp7,9,MePhe8]-substance P (6-11): a comparative study. (1994) (8)
- Pharmaceutical heroin for inhalation: thermal analysis and recovery experiments after volatilisation. (2005) (8)
- Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds. (2020) (8)
- The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome (2013) (8)
- Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer (2019) (8)
- LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial (2022) (8)
- The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue (1997) (8)
- Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet (2013) (8)
- Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide). (2002) (8)
- Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280. (2003) (8)
- Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report (2011) (8)
- Home-based chemotherapy confronts pharmacists with stability and compatibility problems (1992) (8)
- Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours (1999) (8)
- Gas chromatographic determination of ifosfamide in microvolumes of urine and plasma. (1991) (8)
- Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry. (2020) (8)
- Detection of Breast Cancer by Surface-enhanced Laser Desorption/Ionization Time-of-flight Mass Spectrometry Tissue and Serum Protein Profiling (2009) (8)
- Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin. (2004) (8)
- Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. (2016) (8)
- The intravenous to oral switch of taxanes: strategies and current clinical developments. (2020) (8)
- [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency]. (2012) (8)
- Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer. (2004) (8)
- Sorption of Thiotepa to Polyurethane Catheter Causes Falsely Elevated Plasma Levels (2003) (8)
- Volatilisation of diacetylmorphine: in vitro simulation of 'chasing the dragon'. (2006) (8)
- Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. (2020) (8)
- Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel–cisplatin–topotecan in a phase I study (2002) (8)
- Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine. (2019) (8)
- Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans. (1998) (8)
- Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole. (2004) (8)
- Efficacy and Tolerability of a High Loading Dose (25,000 IU Weekly) Vitamin D3 Supplementation in Obese Children with Vitamin D Insufficiency/Deficiency (2014) (8)
- Degradation kinetics of antagonist [Arg6, D-Trp7,9, MePhe8]-substance P [6-11] in aqueous solutions. (1995) (8)
- Treatment of hypertension in an elderly outpatient population in the Netherlands. (2009) (8)
- ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors (2018) (8)
- Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. (2005) (8)
- Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer (2005) (8)
- Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer. (1998) (8)
- Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form. (2005) (8)
- Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures. (2013) (8)
- Degradation kinetics of aplidine, a new marine antitumoural cyclic peptide, in aqueous solution. (2001) (8)
- Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection. (1999) (8)
- Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection. (2002) (8)
- Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells (2013) (7)
- Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285·HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form (2003) (7)
- Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice. (2020) (7)
- Bio-analysis of N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate, methane sulphonate (VileE) by high-performance liquid chromatography with fluorescence detection. (1990) (7)
- Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. (2020) (7)
- Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. (2021) (7)
- Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins. (1993) (7)
- Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2) (2019) (7)
- ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation (2019) (7)
- Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration‐resistant Prostate Cancer Undergoing Hemodialysis (2019) (7)
- Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. (2004) (7)
- Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346. (2006) (7)
- Personalized medicine in oncology: a personal view with myths and facts. (2010) (7)
- Prognostic factors for the clinical effectiveness of fluconazole in the treatment of oral candidiasis in HIV-1-infected individuals. (2002) (7)
- Transposon leads to contamination of clinical pDNA vaccine. (2013) (7)
- 924 Pharmacology of paclitaxel (P) and metabolites in patients with altered liver function (1995) (7)
- Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling (2008) (7)
- Extravasation of topotecan, a report of two cases (1997) (7)
- Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. (2019) (7)
- Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices. (2020) (7)
- Deuterodiacetylmorphine as a marker for use of illicit heroin by addicts in a heroin-assisted treatment program. (2005) (7)
- The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? (2022) (7)
- Analysis of ifosforamide mustard, the active metabolite of ifosfamide, in plasma. (1996) (7)
- Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. (2019) (7)
- Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid (1994) (7)
- Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. (2007) (7)
- Reduction of Cys36-Cys42 and Cys64-Cys74 disulfide bonds in recombinant human granulocyte colony stimulating factor. (1999) (7)
- Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. (2014) (7)
- Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. (2003) (7)
- A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (2009) (7)
- Limited Sampling Models for the Pharmacokinetics of Docetaxel (1997) (7)
- Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG (2007) (7)
- Stabilization of daunorubicin and 4-demethoxydaunorubicin on complexation with octakis(2,6-di-O-methyl)-γ-cyclodextrin in acidic aqueous solution (1992) (7)
- Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically. (2008) (7)
- Rapid Detection of the DPYD IVS14+1G>A Mutation for Screening Patients to Prevent Fluorouracil-Related Toxicity (2012) (7)
- Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. (2009) (7)
- Mitoxantrone extravasation injury. (1987) (7)
- Clinical Relevance: Drug–Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity (2006) (7)
- The degradation of N,N',N"-triethylenephosphoramide in aqueous solutions: a qualitative and kinetic study. (2000) (7)
- A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs (2021) (7)
- Chemical stability of the antitumor drug mitomycin C in solutions for intravesical instillation. (1990) (7)
- Bioanalysis of m-iodobenzylguanidine in plasma by high-performance liquid chromatography after derivatization with benzoin. (1999) (7)
- Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel (1999) (7)
- Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. (2013) (7)
- Human metabolism of [14C]indisulam following i.v. infusion in cancer patients (2005) (7)
- Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma. (1994) (7)
- Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. (2005) (7)
- Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP) (2021) (7)
- HPLC-UV METHOD DEVELOPMENT AND IMPURITY PROFILING OF THE MARINE ANTICANCER AGENT APLIDINE IN RAW DRUG SUBSTANCE AND PHARMACEUTICAL DOSAGE FORM (2001) (7)
- Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow) (2020) (7)
- High-Tech Drugs in Creaky Formulations (2017) (7)
- Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS. (2021) (7)
- Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours (2021) (7)
- Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518 (2002) (6)
- The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate (2007) (6)
- Pharmacokinetics of Etoposide after Oral and Intravenous Administration in Patients with Gastric Carcinoma (1994) (6)
- Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer. (2010) (6)
- Pharmaceutical development of an intravenous dosage form of diacetylmorphine hydrochloride. (2004) (6)
- Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors. (2012) (6)
- A general approach to the interpretation of pH degradation profiles in the presence of ligands (1991) (6)
- Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients (2020) (6)
- High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma. (1998) (6)
- Toxicokinetics of a dipyridamole (Persantin) intoxication: Case report (2011) (6)
- Do geriatric outpatients adhere to medication changes advised after assessment? An exploratory pilot study. (2009) (6)
- 574 Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET) (2010) (6)
- P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. (2019) (6)
- Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report (2004) (6)
- Bioanalytical aspects of clinical mass balance studies in oncology. (2011) (6)
- Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. (2020) (6)
- A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. (2020) (6)
- Sparse Sampling Design for Therapeutic Drug Monitoring of Sequentially Administered Cyclophosphamide, Thiotepa, and Carboplatin (CTC) (2005) (6)
- Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. (2017) (6)
- Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. (2014) (6)
- Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrin. (2008) (6)
- Effect of Cisplatin-Containing Chemotherapy on Lithium Serum Concentrations (1992) (6)
- Thermal stability study of crystalline and novel spray‐dried amorphous nilotinib hydrochloride (2018) (6)
- P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib (2020) (6)
- Impaired quality of life in treatment-seeking obese children of Dutch, Moroccan, Turkish and Surinamese descent (2015) (6)
- Contraindications for anticoagulation in older patients with atrial fibrillation; a narrative review. (2010) (6)
- The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases (2018) (6)
- HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial (2021) (6)
- Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry. (2006) (6)
- Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials (2021) (6)
- Development, validation, and clinical application of a high‐performance liquid chromatography‐tandem mass spectrometry assay for the quantification of total intracellular &bgr;‐decitabine nucleotides and genomic DNA incorporated &bgr;‐decitabine and 5‐methyl‐2′‐deoxycytidine (2019) (6)
- Platinum antitumour agents: A review of (bio)analysis (1992) (6)
- A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute (2020) (6)
- Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography. (2001) (6)
- Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels. (2011) (6)
- Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review (2021) (6)
- Phase I pharmacological study of continuous chronomodulated capecitabine treatment (2020) (6)
- Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography (2004) (6)
- Protein kinase C as a target for new anti-cancer agents (1999) (6)
- Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. (2010) (6)
- Hepatitis during Chloroguanide Prophylaxis (1998) (6)
- Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks (2004) (6)
- High-performance liquid chromatographic bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug vintriptol. (1990) (6)
- Does paclitaxel penetrate into brain tumor tissue? (1995) (5)
- The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [177Lu]Lu-HA-DOTA-TATE in pharmaceutical preparations. (2021) (5)
- Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. (2020) (5)
- Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients (2021) (5)
- Bioavailability of oral etoposide in gastric cancer. (1994) (5)
- PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study (2020) (5)
- Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices. (2006) (5)
- Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin (2011) (5)
- Pharmacokinetics of Zidovudine and Metabolites in a Patient with HIV-Associated Nephropathy and Severe Renal Impairment (1994) (5)
- No relation between docetaxel administration route and high‐grade diarrhea incidence (2020) (5)
- Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients (2017) (5)
- Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry. (2011) (5)
- 567P Exposure-response analyses of dabrafenib and trametinib in melanoma patients (2020) (5)
- Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice (2019) (5)
- Phase I study of vintriptol, a tryptophan ester of vinblastine. (1991) (5)
- Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography. (2000) (5)
- The pharmacokinetics of 124I-rituximab in patients with rheumatoid arthritis (2011) (5)
- Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar☆ (2016) (5)
- Prevalence of Xerostomia and Its Relationship with Underlying Diseases, Medication, and Nutrition: A Descriptive Observational Study (2013) (5)
- Improved high-performance liquid chromatographic separation of decomposition products of prednisolone by adding sulphite to the mobile phase (1980) (5)
- ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study (2021) (5)
- Complexation Study of the Anticancer Agent EO-9 with 2-hydroxypropyl-β-Cyclodextrin (2008) (5)
- From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies (2012) (5)
- Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. (2009) (5)
- Pharmacokinetics of Zidovudine and Acetaminophen in a Patient on Chronic Acetaminophen Therapy (1994) (5)
- Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (2004) (5)
- Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib (2022) (5)
- Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG) (1999) (5)
- [Pleurodesis in malignant pleural effusion]. (1997) (5)
- A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine (2016) (5)
- Lethal toxicity of uracil/tegafur in the treatment of sigmoid carcinoma. (2007) (5)
- EFFECTS OF CYCLODEXTRINS ON N-TRIFLUOROACETYLDOXORUBICIN-14-VALERATE (AD-32) STABILITY AND SOLUBILITY IN AQUEOUS MEDIA (1991) (5)
- Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311. (2005) (5)
- Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug. (1995) (5)
- Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer (2017) (5)
- High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma. (1995) (5)
- EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studies. (2007) (5)
- The pharmacokinetics of 124I-rituximab in patients with rheumatoid arthritis (2011) (5)
- Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry. (2015) (5)
- Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series (2022) (5)
- Thermal study of pazopanib hydrochloride (2017) (5)
- Didanosine, a new antiretroviral drug (1992) (5)
- DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A. (2018) (5)
- Identification of two new serum protein profiles for renal cell carcinoma. (2009) (5)
- Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine. (2015) (5)
- Follow up survey for implementation of fixed-dosing of monoclonal antibodies (2020) (5)
- Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs. (2015) (5)
- Chemical stability of n trifluoroacetyldoxorubicin 14 valerate ad 32 in aqueous media and after liposome encapsulation (1989) (5)
- Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. (2001) (5)
- Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology (2022) (5)
- Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study (2019) (5)
- Stereoselectivity in the mechanism of acid hydrolysis of mitomycins. (1987) (5)
- ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib (2021) (5)
- DEVELOPMENT OF AN HPLC METHOD WITH UV DETECTION FOR THE PHARMACEUTICAL QUALITY CONTROL OF THE NOVEL MARINE ANTICANCER AGENT KAHALALIDE F (2001) (5)
- Development and Validation of Limited-Sampling Models for the Antiretroviral Agent Zidovudine (1993) (5)
- Methylphenidate for cerebral palsy with choreoathetosis. (2000) (5)
- Stability of famotidine in commonly used nutritional infusion fluids. (1988) (4)
- A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry (2010) (4)
- Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. (2020) (4)
- Eribulin dosing in patients with advanced solid tumors and hepatic impairment. (2011) (4)
- Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry. (2016) (4)
- [Clozapine use and abrupt smoking cessation; a potentially life-threatening combination]. (2009) (4)
- Stability of corticosteroids under anaerobic conditions (1980) (4)
- Pharmacokinetics of Cyclophosphamide and Thiotepa in a Conventional Fractionated High-Dose Regimen Compared With a Novel Simplified Unfractionated Regimen (2009) (4)
- Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry. (2007) (4)
- Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS (2017) (4)
- Bioanalytical method for the simultaneous quantification of irinotecan and its active metabolite SN-38 in mouse plasma and tissue homogenates using HPLC-fluorescence. (2020) (4)
- PRESCRIPTION ERROR RESULTING IN VALPROIC ACID INTOXICATION (2004) (4)
- A Phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF 120918) in combination with 2.0 mg oral topotecan in cancer patients (2004) (4)
- Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice (2004) (4)
- A multi-gram-scale stereoselective synthesis of Z-endoxifen. (2018) (4)
- A comparison of the radiochemical stability of different iodine-131 labelled metaiodobenzylguanidine formulations for therapeutic use (1994) (4)
- Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion (1996) (4)
- P-gp and taxanes (2014) (4)
- Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur. (1997) (4)
- Bioanalysis of the novel peptide anticancer drug kahalalide F in human plasma by h.p.l.c. under basic conditions coupled with positive turbo‐ionspray tandem mass spectrometry (2002) (4)
- Analysis of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and Its Phase I and Phase II Metabolites in Mouse Urine Using LC–UV–MS–MS (2011) (4)
- Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility (2005) (4)
- Phase I study of combined treatment with the oral alkyl-lysophospholipid (ALP) Perifosine and radiation in patients with advanced solid tumors. (2004) (4)
- Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study (2019) (4)
- Palladium‐induced granulomas analysed with inductively coupled plasma mass spectrometry (2018) (4)
- Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor (2010) (4)
- Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol (2004) (4)
- High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates. (2011) (4)
- Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error (2014) (4)
- Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies (2002) (4)
- Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids. (1993) (4)
- Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin (2018) (4)
- Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. (2020) (4)
- Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study. (2019) (4)
- High Performance Liquid Chromatographic Analysis of The Cardioprotective Agent Dexrazoxane in Human Plasma and Urine (1997) (4)
- 486PINDIVIDUALIZED PHARMACOKINETICALLY-GUIDED DOSING OF PAZOPANIB: A FEASIBILITY STUDY IN CANCER PATIENTS. (2014) (4)
- Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue. (2021) (4)
- Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. (2015) (4)
- Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg(6), D-Trp(7,9), MePhe(8)] substance P[6-11]. (1999) (4)
- CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis. (2011) (4)
- p53 selected as molecule of the year 1993 (1994) (4)
- Degradation of suramin in aqueous solutions (1997) (4)
- Impact of age on exposure to oral antiandrogen therapies in clinical practice (2018) (4)
- Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection. (2012) (4)
- Incidence of Hematologic Toxicity in Older Adults Treated with Gemcitabine or a Gemcitabine-Containing Regimen in Routine Clinical Practice: A Multicenter Retrospective Cohort Study (2014) (4)
- Decomposition of mitomycin and anthracycline cytostatics in cell culture media. (1986) (4)
- The preparation of radiolabeled monoclonal antibodies for human use. (2009) (4)
- Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab. (2011) (4)
- Biodetermination of N-(deacetyl-O-4-vinblastoyl-23)-L-tryptophan, a metabolite of vintriptol, by high-performance liquid chromatography with fluorescence detection. (1992) (4)
- [Severe phenytoin intoxication in patients with hypoalbuminaemia]. (2007) (4)
- Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose (2020) (4)
- Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours (2021) (4)
- Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice (2017) (4)
- Determination of N,N',N"-triethylenthiophosphoramide in biological samples using capillary gas chromatography. (1997) (4)
- A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer (2019) (4)
- [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation]. (2010) (4)
- Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics (2021) (4)
- ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. (2021) (4)
- Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors (2016) (4)
- Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer (2016) (4)
- Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202). (2012) (4)
- Phase I pharmacological study of continuous chronomodulated capecitabine treatment (2018) (4)
- DNA vaccination in oncology: current status, opportunities and perspectives. (2010) (3)
- Effect of Heat Treatment of Potentially Infected Blood Samples on Therapeutic Drug Monitoring of Selected Drugs (1993) (3)
- ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. (2021) (3)
- Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. (2020) (3)
- A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors (2021) (3)
- Bioanalysis of radioiodine labelled meta-iodobenzylguanidine, its metabolites and free radioiodide in body fluids (1997) (3)
- Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography. (2003) (3)
- Population Pharmacokinetics of Intracellular 5-Fluorouridine 5′-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine (2021) (3)
- Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial (2021) (3)
- Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer (2021) (3)
- Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization? (2010) (3)
- Limited sampling models for the antiretroviral agent didanosine (1995) (3)
- Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. (2017) (3)
- Effects of Cyclosporine A on Single-Dose Pharmacokinetics of Intravenous Itraconazole in Patients With Hematologic Malignancies (2008) (3)
- Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study (2020) (3)
- The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts. (1999) (3)
- Urinary excretion of paclitaxel and metabolites in a large series study (1998) (3)
- Pharmacologic Study of Paclitaxel Administered With or Without the Cytoprotective Agent Amifostine, and Given as a Single Agent or in Combination With Epirubicin and Cisplatin in Patients With Advanced Solid Tumors (2001) (3)
- Nevirapine plus didanosine: once or twice daily combination? (2000) (3)
- Universal access to quality medicines: prioritisation of a-priori solutions. (2012) (3)
- Oral Bioavailability of Low Dose (20mg) ‘Home-Made’ Etoposide Capsules (1996) (3)
- Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium. (2019) (3)
- Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients (2019) (3)
- Prevalence of xerostomia and its relationship with underlying diseases, medication and nutrition, a descriptive observational study (2013) (3)
- ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study. (2020) (3)
- Serum proteomic profiling of advanced gastric cancer and identification of proteomic changes following response to epirubicin, cisplatin and capecitabine chemotherapy as diagnostic and predictive biomarkers (2007) (3)
- High-performance liquid chromatographic method for the analysis of 10-ethyl-10-deaza-aminopterin and metabolites in plasma. (1990) (3)
- Assessment of Performance of Manufacturing Procedures in a Unit for Production of Investigational Anticancer Agents, Using a Mixed Effects Analysis (2007) (3)
- Evaluation of two immunoassays for the determination of zidovudine in biological matrices. (1995) (3)
- 2-hydroxypropyl-β-cyclodextrin extracts 2-phenylphenol from silicone tubing (2004) (3)
- The impact of the ABC transporters P-gp and BCRP on the oral bioavailability and brain penetration of erlotinib using drug transporter knockout mouse models. (2007) (3)
- Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium. (2017) (3)
- 940 Phase I and pharmacokinetic study of topotecan (T) in combination with oral etoposide (E) (1995) (3)
- Mass balance study with ixabepilone using Accelerator Mass Spectrometry. (2004) (3)
- Quality control of protein and peptide drugs : monoclonal antibodies and some biological response modifiers derived by recombinant DNA technology (1993) (3)
- Liquid chromatography‐tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine (2017) (3)
- Should Non-Nucleoside Reverse Transcriptase Inhibitors be Combined? (2005) (3)
- Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients (2013) (3)
- Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244) (1996) (3)
- Ocular complications of the acquired immunodeficiency syndrome (1993) (3)
- A highly sensitive bioanalytical method for the quantification of vinblastine, vincristine, vinorelbine and 4-O-deacetylvinorelbine in human plasma using LC-MS/MS. (2022) (3)
- The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib. (2021) (3)
- 606 Phase I and pharmacological study of AP5346, an HPMA copolymer-linked DACH platinum therapeutic, in patients with solid progressive tumors (2004) (3)
- The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244). (1995) (3)
- Quantification of farnesylmethylcysteine in lysates of peripheral blood mononuclear cells using liquid chromatography coupled with electrospray tandem mass spectrometry: pharmacodynamic assay for farnesyl transferase inhibitors. (2006) (3)
- A Phase 1 Dose‐Escalation Study of Low‐Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors (2020) (3)
- Degradation kinetics of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) in aqueous solution in the presence of γ-cyclodextrin (1994) (3)
- The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials (2022) (3)
- Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification. (2021) (3)
- The domain architecture of the protozoan protein J-DNA–binding protein 1 suggests synergy between base J DNA binding and thymidine hydroxylase activity (2019) (3)
- Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa (2020) (3)
- Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry. (2011) (3)
- Reply to T. Magnes et al. (2016) (2)
- Phase I and pharmacological study of orally administered indibulin in advanced solid tumors (2007) (2)
- MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial (2022) (2)
- Kinetics and mechanism of the degradation of la-acetylmitomycin C in aqueous solution (1993) (2)
- Computation of mitomycin C-γ-cyclodextrin complex stability constant (1993) (2)
- Corrigendum to "Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine" [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893-894 (2012) 92-100]. (2016) (2)
- Signal transduction pathways: New targets in oncology (1993) (2)
- ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability (2021) (2)
- A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. (2004) (2)
- Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk (2006) (2)
- Effect of oxaliplatin-capecitabine first-line chemotherapy and tumor response on serum proteomic profiles in advanced colorectal cancer and identification of diagnostic biomarkers. (2006) (2)
- Population pharmacokinetics and pharmacodynamics of mitomycin C during intra-operative hyperthermic intraperitoneal chemotherapy (2009) (2)
- 116 The pharmacokinetics of topotecan (T) and its carboxylate (C) form following separate intravenous administration to the dog (1995) (2)
- P04.91 ABC-drug efflux transporters at the blood-brain barrier limit the efficacy of treatment against primary and secondary brain tumors (2018) (2)
- Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting (2022) (2)
- Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer. (2020) (2)
- Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection. (1993) (2)
- Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors (2021) (2)
- Model‐Based Evaluation of Similarity in Pharmacokinetics of Two Formulations of the Blood‐Derived Plasma Product C1 Esterase Inhibitor (2012) (2)
- Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar (2004) (2)
- Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrin. (2008) (2)
- Visual Compatibility of Ondansetron and Dexamethasone (1991) (2)
- Phase I and pharmacokinetic study of ecteinascldin-743 (ET-743) given as a one hour infusion every 21 days (1997) (2)
- A phase I dose-escalation trial of bi-daily (BID) weekly oral docetaxel as ModraDoc006 in combination with ritonavir (2016) (2)
- Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen? (2008) (2)
- Chemical Stability of Suramin in Commonly used Infusion Fluids (1990) (2)
- Photophobia in a Patient with High Indinavir Plasma Concentrations (2003) (2)
- Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244) (2004) (2)
- Co-trimoxazole and stavudine interference in a high-performance liquid chromatographic analysis for didanosine in human plasma. (1998) (2)
- CAMPTOTHECINS: UNFOLDING THEIR ANTICANER POTENTIAL (2000) (2)
- Phase I, pharmacokinetic, and pharmacodynamic study of carboplatin and topotecan administered in two different schedules. (2016) (2)
- Cannulation of the jugular vein in mice (2005) (2)
- DOES PACLITAXEL PENETRATE INTO BRAIN TUMOR TISSUE ? AUTHOR'S REPLY (1995) (2)
- Phase II and pharmacological study of oral paclitaxel plus cyclosporine A in anthracycline pretreated metastatic breast cancer (2005) (2)
- P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. (2021) (2)
- Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. (2014) (2)
- Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma. (2012) (2)
- The novel orally available taxane derivative BMS-275,183 is a substrate for P-glycoprotein (Pgp, MDR1) and MRP2 and interacts with benzimidazole proton pump inhibitors. (2006) (2)
- No pharmacokinetic drug–drug interaction between nevirapine and paclitaxel (2005) (2)
- Analysis of 4-demethoxydaunorubicin and metabolites in plasma and urine. (1988) (2)
- [Miltefosine: a new remedy for leishmaniasis]. (2006) (2)
- Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II (2017) (2)
- Intoxication with Trazodone Caused by Dirty Facsimile Machine (2009) (2)
- Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence” (2021) (2)
- Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates. (2021) (2)
- A dose-dependent delayed hypersensitivity reaction to acetaminophen after repeated acetaminophen intoxications (1998) (2)
- Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors (2009) (2)
- The impact of Ramadan fast on BMI and cardiometabolic factors in ethnic obese adolescents. (2014) (2)
- Cancer Resistance Protein in Clinical Drug-Drug Interactions Methotrexate and Benzimidazoles : Potential Role for Breast Mechanism of the Pharmacokinetic Interaction between Updated (2004) (2)
- Degradation kinetics of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) in aqueous solution (1988) (2)
- In vitro immunosuppressive activities of recently developed anthracycline cytostatics. (1988) (2)
- Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel? (2019) (2)
- Degradation of azaglycinamido residues in model tripeptides derived from goserelin. (2000) (2)
- The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab (2011) (2)
- Quantification of sunitinib in sweat secretion. (2010) (2)
- Toxicological analysis of azide and cyanide for azide intoxications using gas chromatography (2020) (2)
- Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B 2 ) into Milk (cid:1) (2007) (2)
- Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients. (2021) (2)
- The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab (2011) (2)
- Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma (2019) (2)
- Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer (2022) (2)
- Development and validation of a liquid chromatography‐tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine (2018) (2)
- Gemcitabine metabolite, 2’,2’-difluorodeoxyuridine (dFdU), can be phosphorylated and incorporated into nucleic acids (2007) (2)
- Abstract 6322: The role of multidrug efflux transporters and CYP3A in the pharmacokinetics and tissue distribution of abemaciclib and its active metabolites (2020) (1)
- A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors. (2006) (1)
- Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study (2021) (1)
- Population pharmacokinetic modelling to support the evaluation of preclinical pharmacokinetic experiments with lorlatinib. (2021) (1)
- Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer (2012) (1)
- Cancer Therapy : Preclinical Abcc 4 Together with Abcb 1 and Abcg 2 Form a Robust Cooperative Drug Ef fl ux System That Restricts the Brain Entry of Camptothecin Analogues (2013) (1)
- Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue. (2022) (1)
- Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. (2006) (1)
- Bioanalysis of the investigational anti-tumour drug 5,10-dideaza-5,6,7,8-tetrahydrofolic acid by high-performance liquid chromatography with ultraviolet detection. (1992) (1)
- Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer (2019) (1)
- Development and validation of an LC-MS/MS method for the quantification of imatinib and imatinib-d8 in human plasma for the support of an absolute bioavailability microdose trial. (2020) (1)
- the assessment of duration of contraceptive use after (2012) (1)
- The effect of heptakis (2,6-di-O-methyl)-γ-cyclodextrin on mitomycin C stability in aqueous solution (1990) (1)
- Tandem mass spectrometry of small-molecule signal transduction inhibitors: Accurate-m/z data to adapt structure proposals of product ions. (2020) (1)
- The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer (2022) (1)
- Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue. (2022) (1)
- Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum. (2022) (1)
- Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry (2022) (1)
- Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology (2020) (1)
- Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients (2018) (1)
- Chemo-resistance of brain tumors: The role of the blood-brain barrier with emphasis on P-glycoprotein (2005) (1)
- Short communication Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report (1994) (1)
- Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors. (2010) (1)
- HAART, or just mini-HAART? (2001) (1)
- Chemical stability of the new antitumour agent intoplicine in infusion fluids. (1993) (1)
- Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry (2017) (1)
- Abstract 3791: Milk thistle as an inhibitor of PXR-mediated CYP3A4 induction (2012) (1)
- Bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug LL-D49194α1☆ (1989) (1)
- [The pharmacokinetics of monoclonal antibodies]. (2007) (1)
- A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (2019) (1)
- Purine and pyrimidine metabolism: still a black box? (2005) (1)
- The risks of handling cytotoxic drugs (1990) (1)
- [Thalidomide once more in the spotlight]. (1999) (1)
- Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer (2021) (1)
- Suppression of migration inhibition factor (MIF) production by mitomycins in vitro. (1986) (1)
- Severe Lactic Acidosis in a Diabetic Patient after Ethanol Abuse and Floor Cleaner Intake (2014) (1)
- ADME‐Enabling Technologies in Drug Design and Development. Edited by Donglu Zhang and Sekhar Surapaneni (2013) (1)
- New cytotoxic drugs and targets in oncology (1992) (1)
- Abstract 1518: P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) limit sunitinib brain accumulation which can be enhanced by oral elacridar treatment (2010) (1)
- Lack of a pharmacokinetic interaction between Rifampin and Didanosine (1996) (1)
- Abstract 5218: Breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) transport ibrutinib and may restrict its oral availability and brain accumulation, whereas CYP3A4 limits ibrutinib oral availability (2017) (1)
- A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling. (2023) (1)
- Liquid chromatographic assay with fluorescence detection to determine ajmaline in serum from patients with suspected Brugada syndrome. (2010) (1)
- Stability of corticosteroids under anaerobic conditions (1984) (1)
- A population pharmacokinetic model for Cremophor EL using nonlinear mixed-effect modeling: model building and validation (2002) (1)
- Abstract 761: Phase I interaction study of docetaxel with supplementation of St. John's wort (2012) (1)
- Development and validation of a UPLC-MS/MS method with a broad linear dynamic range for the quantification of morphine, morphine-3-glucuronide and morphine-6-glucuronide in mouse plasma and tissue homogenates. (2020) (1)
- Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA (2013) (1)
- Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients (2022) (1)
- Degradation kinetics of the antitumour drug nimustine (ACNU) in aqueous solution (1993) (1)
- Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer (2019) (1)
- 70P Fluoropyrimidine (FP) dose individualization based on pretreatment uracil levels: Safety and pharmacokinetic (PK) analysis from the Alpe2U study (2022) (1)
- Abcc 4 together with Abcb 1 and Abcg 2 form a robust co-operative drug efflux system that restricts the brain entry of camptothecin analogs (2013) (1)
- 2-Hydroxypropyl-beta-cyclodextrin extracts 2-phenylphenol from silicone tubing. (2004) (1)
- Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites (2021) (1)
- Pharmacotherapy of Hospitalised HIV-Infected Patients in a General Hospital during 1990, 1997 and 2001 (2003) (1)
- 549 Liver toxicity: a predictable and manageable toxicity for kahalalide F (KF) (2003) (1)
- Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors (2010) (1)
- Phase I trials with ET-743, a marine derived (MD) anticancer agent (1999) (1)
- Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter] (2020) (1)
- Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure. (2020) (1)
- The domain architecture of JBP1 suggests synergy between J-base DNA binding and thymidine hydroxylase activity (2018) (1)
- Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells (2018) (1)
- An Open-Label Phase I Pharmacokinetic Study of [14c] Bendamustine in Patients with Relapsed or Refractory Malignancy (2011) (1)
- Development and validation of a high‐performance liquid chromatography‐tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma (2018) (1)
- Does antisense make sense? (1993) (1)
- The pharmacokinetics of reduced folates after intraperltoneal and intravenous administration of racemic [6S,R]-folinic acid (2004) (1)
- Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir (2020) (1)
- The effect of admission to a geriatric ward on medication use: 2002 versus 1985 (2006) (1)
- Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients (2022) (1)
- A Taste of Taxol (2001) (1)
- 581 An Adaptive, 2-stage, Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients with Advanced Solid Tumors (2012) (1)
- Authors’ Reply to Toda: “The Effects of Fall-Risk-Increasing Drugs on Postural Control: A Literature Review” (2013) (1)
- Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice (2021) (1)
- P12 SELDI-TOF MS serum protein profiling predicts poor prognosis renal cancer patients (2007) (1)
- Ultrasensitive Bioanalytical Assays for Cytotoxic Drugs: Focus on Locally Administered Anti-Cancer Agents (2008) (1)
- Re-use of mitomycin C in the treatment of superficial tumours of the urinary bladder: an evaluation in view of its chemical stability. (1987) (1)
- [Hyperglycaemia during treatment with everolimus]. (2014) (1)
- Acute poisoning after oral intake of a toluene-containing paint thinner (2002) (1)
- Chemical stability of cyclophosphamide, trofosfamide, and 2- and 3-dechloroethylifosfamide in aqueous solutions (1996) (1)
- Clinical Pharmacology of Carboplatin Administered in Alternating Sequence with Paclitaxel in Patients with Non-Small Cell Lung Cancer: A European Cancer Centre (ECC) Study (1996) (1)
- Effect of cyclodextrins on anthracycline stability in acidic aqueous media (1988) (1)
- Abstract LB-49: ABC transporters in the blood-brain barrier limit the brain penetration of the PARP inhibitor ABT-888 (2010) (1)
- Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cancer (2022) (1)
- Purine and pyrimidine metabolism: still a black box? (1994) (1)
- Factors Affecting Long-Term Safety of Trastuzumab in Patients with Early HER2-Positive Breast Cancer (2014) (1)
- Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy” (2015) (1)
- Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review (2019) (1)
- Gemcitabine a nd P aclitaxel: P harmacokinetic and P harmacodynamic I nteractions i n P atients With N on-Small-Cell L ung C ancer (1999) (0)
- 654 Predictive value of a dextromethorphan phenotyping test for endoxifen exposure (2010) (0)
- An improved system for anaerobic stability investigations in solutions at increased temperatures (1980) (0)
- Abstract 4419: The role of ABC transporters in PhIP-induced colon carcinogenesis (2012) (0)
- Randomized phase I study of weekly or every other week gemcitabine (GEM) plus cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC) (2000) (0)
- Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine (2019) (0)
- Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (2013) (0)
- ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. (2022) (0)
- Erratum to “Development and validation of a liquid chromatography–ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285·HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form” [J. Chromatogr. A 1020 (2003) 251–258] (2004) (0)
- Pharmacokinetics of etoposide after oral and intravenous administration in patients with stomach carcinoma (1994) (0)
- Abstracts of Dutch doctoral theses (2005) (0)
- Biomarqueurs destines au cancer du sein (2005) (0)
- O1.13: The relationship between medication-use and gait variability in frail elderly: From FRIDs to Frail (2014) (0)
- 1243 POSTER Eribulin Mesylate Pharmacokinetics in Patients With Advanced Solid Tumours Receiving Rifampicin (2011) (0)
- Lithium pharmacokinetics and cisplatin-based chemotherapy (1995) (0)
- Exposure-Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer. (2023) (0)
- The first issue of Pharmacy World & Science (2005) (0)
- Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa. (2023) (0)
- Searching for early breast cancer biomarkers by serum protein profiling in Prospect-EPIC (2008) (0)
- Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9 (2004) (0)
- High-Tech Drugs in Creaky Formulations (2017) (0)
- The performance of model-based versus rule-based phase I clinical trials in oncology (2016) (0)
- The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome (2013) (0)
- Reply to Arya and Agarwal. (2013) (0)
- Volume Contents (2004) (0)
- The PARP inhibitor olaparib (LynparzaTM) has shown an acceptable toxicity profile as monotherapy at doses up to 400 mg twice daily with encouraging signs of anti-tumor activity, especially in BRCA mutation carriers. Based on its mode of action, olaparib (2020) (0)
- OATP1B1 mediates transport of gimatecan and BNP1350 and can be inhibited by several classical ABCB1 and/or ABCG2 inhibitors (2008) (0)
- More favorable cardiometabolic profile in overweight children with type 1 diabetes as compared to overweight non-diabetic controls: a case-control study (2010) (0)
- ‘Flooding’ of the lungs and severe dyspnea in a patient with bronchoalveolar carcinoma (2011) (0)
- Solubility and Bioavailability Improvement of Pazopanib Hydrochloride ( PZH ) (2017) (0)
- Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies (2022) (0)
- Abstract 1294: Metabolism and excretion of eribulin in patients with advanced solid tumors (2011) (0)
- 829P A proof of concept study of sequential treatment with the HDAC inhibitor vorinostat plus BRAF and MEK inhibitors in BRAFV600 mutated melanoma (2022) (0)
- Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis 1 (2010) (0)
- [Warning: sedatives for pets, effect on their master]. (1994) (0)
- Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site (2023) (0)
- Boosting oral docetaxel (modradoc001) with different cyp3a4 inhibitors (2010) (0)
- Development of a Uplc-Ms/Ms Assay for the Quantitative Determination of Capecitabine, 5’-Deoxy-5-Fluorocytidine (5’-Dfcr), 5’-Deoxy-5-Fluorouridine (5’-Dfur), 5’-Fluorouracil (5-Fu), and Α-Fluoro-Β-Alanine (Fbal) (2022) (0)
- Quantitative LC-MS/MS analysis of 5-hydroxymethyl-2'-deoxyuridine to monitor the biological activity of J-binding protein. (2020) (0)
- Modulation of cytochrome P450 (CYP) and P-glycoprotein (P-gp) and BCR activity in gut wall and liver as major determinants of poor oral bioavailability of anticancer drugs: preclinical and clinical studies (2000) (0)
- Cancer Therapy : Preclinical P-Glycoprotein , CYP 3 A , and Plasma Carboxylesterase Determine Brain and Blood Disposition of themTOR Inhibitor Everolimus ( A fi nitor ) in Mice (2014) (0)
- Derivatization Reactions and Kinetics in Liquid Chromatography (2021) (0)
- Development and Validation of a Stability-indicating HPLC Method for the Analysis of Cabazitaxel in Jevtana® Concentrate-solvent Leftover Samples (2020) (0)
- Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab (2012) (0)
- Prevalence and predictors of impaired glucose metabolism in an overweight/obese pediatric multi-ethnic cohort (2010) (0)
- P‐glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) restrict the brain penetration of the Janus family of tyrosine kinase (JAK) inhibitor CYT387 (2013) (0)
- Determination of the bioequivalence of a new oral topotecan formulation relative to the current formulation in patients with advanced solid tumors (2008) (0)
- O1.13: The relationship between medication-use and gait variability in frail elderly: From FRIDs to Frail: Abstracts of the 10th International Congress of the European Union Geriatric Medicine Society - Geriatric Medicine Crossing Borders (2014) (0)
- ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability. (2022) (0)
- Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) (2014) (0)
- Abstracts of papers (2005) (0)
- Chloroquine Administration in Breastfeeding Mothers Associates with Increased HIV-1 Plasma Viral Loads (2020) (0)
- The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals (2001) (0)
- Abstract 966: Effect of ABC drug transporters (BCRP, MDR1, MRP2) on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA . (2013) (0)
- Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) (2015) (0)
- Use of chloroquine in reducing mother to child transmission of HIV-1 during breastfeeding (2009) (0)
- The Effect of Cyclodextrins on the Mitomycin Stability in Acidic Aqueous Media (1988) (0)
- P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO) (2021) (0)
- Simultaneous Quantitative Analysis of EO9 (Apaziquone) and its Conversion Products EO5a and EO9-Cl in Human and Dog Urine by High-Performance Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry (2009) (0)
- Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer (2015) (0)
- [Ovarian carcinoma: various aspects of intraperitoneal chemotherapy]. (1988) (0)
- Liquid chromatography–tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma B Analytical technologies in the biomedical and life sciences (2016) (0)
- Decrease of Patient Costs in the Netherlands: a Cost of Illness Study in Metastatic Non Small Cell Lung Cancer (Nsclc). (2015) (0)
- ABC- transporter studies of Gimatecan (7-t-butoxyiminomethylcamptothecin) in comparison to topotecan (2006) (0)
- Buparlisib is a brain penetrable pan-PI3K inhibitor (2018) (0)
- Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its hemolytic potential (2004) (0)
- Cortisol as biomarker for CYP17 inhibition in mCRPC patients treated with abiraterone acetate. (2021) (0)
- P-5-560 High concentration of daunorubicin and daunorubicinol in human malignant astrocytomas after systemic administration of liposomal daunorubicin (1997) (0)
- Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. (2019) (0)
- Impact of age on exposure to oral antiandrogen therapies in clinical practice (2018) (0)
- Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction B Analytical technologies in the biomedical and life sciences (2017) (0)
- Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. (2021) (0)
- PCN191 - COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN (2018) (0)
- Response to “Commets on ‘Systematic Study on the Chemical Stability of the Prodrug Antitumor Agent Carzelesin (U-80,244)’” (1997) (0)
- Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood‐brain barrier and may be an attractive agent for treatment of glioblastoma (2009) (0)
- First clinical experience with technetium-99m labeled PEG-liposomes for the detection of infection and inflammation (1998) (0)
- New discriminatory serum protein profiles in breast cancer patients (2004) (0)
- P-138: Gait and patient characteristics that discriminate fallers from non-fallers in a geriatric population (2015) (0)
- The Authors’ Reply (2006) (0)
- Where are the immunotoxins in the clinic? (1993) (0)
- Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (2020) (0)
- SELDI-TOF MS serum protein profiling predicts poor prognosis in renal cancer patients (2007) (0)
- 126 ENANTIOSELECTIVE QUANTITATION OF (R)- AND (S)- ALPRENOLOL BY GC/MS IN SALIVA AND PLASMA (1995) (0)
- EXTH-72. CONTINUOUS INFUSION STUDIES REVEAL THE POTENCY OF ELACRIDAR TO ACT AS A PHARMACO-ENHANCER FOR TREATMENT OF INTRACRANIAL DISEASES BY INHIBITING ABCB1 AND ABCG2 AT THE BLOOD-BRAIN BARRIER (2020) (0)
- Abstract 1268: The impact of P-glycoprotein, breast cancer resistance protein and CYP3A on pharmacokinetics and metabolism of galunisertib (2019) (0)
- The use of novel pharmacodynamic end-points in early clinical trials: focus on farnesyltransferase inhibitors (2003) (0)
- Selected new developments in oncology. (2010) (0)
- Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study. (2011) (0)
- Electrochemistry of Potentially Bioreductive Alkylating Quinones. Part 4. Qualitative and Quantitative Structure-Activity Relationships of Aziridinylquinones. (1993) (0)
- Abstract 3771: Splenic macrophages induce chemotherapy resistance via DNA damage repair (2014) (0)
- RECOVERY AFTER ECSTASY INTOXICATION. AUTHORS' REPLY (1999) (0)
- Abstracts of papers symposium disposition and delivery of peptide drugs (2005) (0)
- A phase Istudy ofprolonged continuous infusion oflowdoserecombinant interleukin-2 inmelanoma andrenal cellcancer.PartI:clinical aspects (1992) (0)
- Chapter 3 Multidrug resistance protein 2 ( Mrp 2 ; Abcc 2 ) is an important determinant of paclitaxel pharmacokinetics (2009) (0)
- Coadministration o f C yclosporine S trongly E nhances t he Oral B ioavailability o f D ocetaxel (2001) (0)
- Bioavailability andpharmacokinetics oforal topotecan: a new topoisomerase Iinhibitor (1996) (0)
- [Management recommendations in patients with methotrexate intoxication]. (2007) (0)
- Abstract 4187: A rapid and robust transgenic high-grade glioma mouse model for therapy-intervention studies (2010) (0)
- Compound Mrp2 (Abcc2) and other drug transporter knockout mice to study determinants of pharmacokinetics, toxicity risks and possible therapy optimization for anticancer drugs (2003) (0)
- Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose? (2022) (0)
- Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form. (2003) (0)
- Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir (2021) (0)
- The short- and long-term impact of the Ramadan fast on body weight and cardiometabolic factors: a pilot study in an ethnic obese adolescent cohort. (2013) (0)
- Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors. (2009) (0)
- Is age just a number? A population pharmacokinetic study of gemcitabine (2022) (0)
- Bioanalysis of the investigational anti-tumour drug 5,10-dideaza-5,5,7,8-tetrahydrofolic acid by high-performance liquid chromatography with ultraviolet with ultraviolet detection (1992) (0)
- 1 Cancer drugs clinical pharmacology: Relevance in oncology (1995) (0)
- Impact of ABC transporters on the disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine) and its mutagenic metabolites in vivo (2009) (0)
- Abstracts of Dutch doctoral theses (2005) (0)
- Transport van taxoiden over de bloed-hersenbarrière en penetratie van tumoren in het centrale zenuwstelsel: een preklinische farmacologische studie en een klinische 'proof of concept' test bij glioom-patiënten. (1999) (0)
- Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs (2022) (0)
- Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment (2016) (0)
- The effectiveness of a daily practice clinical weight management program on cardiometabolic risk in obese children (2010) (0)
- Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin (2004) (0)
- A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients (2023) (0)
- Abstract 5718: Implementation of μ-Image Guided Radio-Therapy in the treatment of experimental glioma mouse models: Assessment of the potential of agents that interfere with DNA repair (2012) (0)
- Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites (2022) (0)
- Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6-11} (2004) (0)
- leishmaniasis: a systematic review (2014) (0)
- Drug Formulations: How these Affects Anticancer Drug (2014) (0)
- Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses (2012) (0)
- Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma (2019) (0)
- The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials (2022) (0)
- [Demethylating medication in myelodysplastic syndrome]. (2012) (0)
- 455 Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080: a modeling and simulation approach (2010) (0)
- DPYD single nucleotide polymorphisms (SNPs) and haplotypes in patients (pts) with metastatic colorectal cancer and toxicity of capecitabine. (2010) (0)
- Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study (2017) (0)
- Changing of the guard (1994) (0)
- The pharmacokinetics of didanosine are equivalent in a once daily and twice daily regimen (1998) (0)
- IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women (2021) (0)
- Biomedical Analysis : Functional and structural characterization (2006) (0)
- Microsoft Word-23340919-file00 (2009) (0)
- HEPARINE IN HET HEPARINESLOT (1991) (0)
- Phenytoin monitoring in HIV-positive individuals Is there an interaction with zidovudine ? (1993) (0)
- Use of serum proteins identified by proteomics to predict prognosis in patients with metastatic renal cell cancer (mRCC) and comparison to the currently used MSKCC survival model. (2009) (0)
- CMET-12. TUMOR CELL DETECTION BY IMMUNOFLOW CYTOMETRY AND BRAF MUTATION ANALYSIS IN CEREBROSPINAL FLUID OF MELANOMA PATIENTS WITH SUSPECTED LEPTOMENINGEAL METASTASES (2017) (0)
- New discriminatory serum protein profiles in breast cancer patients. (2004) (0)
- Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review (2021) (0)
- Abstract LB-210: Impact of ABC-transporters in the blood-brain barrier on the efficacy of the PARP inhibitor ABT-888 against transplanted and spontaneous murine brain tumors (2011) (0)
- Assay performance and stability of uracil and dihydrouracil in clinical practice (2023) (0)
- Taxol® metabolism in human plasma (1993) (0)
- Randomized phase I and pharmacological study of weekly or 2-weekly gemcitabine and cisplatin in advanced non-small cell lung cancer. (2002) (0)
- Use of leftovers of monoclonal antibody products after partial extraction – A microbiological safety study (2020) (0)
- DDRE-01. ACQUIRED AND INTRINSIC RESISTANCE TO VEMURAFENIB IN BRAFV600E-DRIVEN MELANOMA BRAIN METASTASES (2020) (0)
- Molecular imaging of PgP/BCRP inhibition at the blood brain barrier using elacridar and [11C] erlotinib PET (2016) (0)
- Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice. (2023) (0)
- A didemnin compound-containing pharmaceutical formulation (1999) (0)
- Impact of polymorphisms in the CYP2B6 gene on the pharmacokinetics of cyclophosphamide and thiotepa. (2006) (0)
- The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases (2018) (0)
- P133 reversed - phase high performance liquid chromatography and capillary electrophoresis in the stability study of the neuropeptide growth factor antagonist [ARG6, D-TRP7,9, MEPHE8]-substance P {6–11}: A comparative study (1994) (0)
- Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs. (2022) (0)
- Abstracts of papers Pharmaceutical and biomedical analysis meeting (2005) (0)
- Phase I study of combination treatment with PTK 787/ZK 222584 (PTK/ZK) and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and toxicity analysis. (2009) (0)
- Population Pharmacokinetics of Intracellular 5-Fluorouridine 5′-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine (2021) (0)
- MINIREVIEW P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy (2004) (0)
- Abstract 697: Mesenchymal stem cell-induced resistance: Implications for reversible resistance (2011) (0)
- Abstracts of lectures and posters pharmaceutical and biomedical analysis meeting (1994) (0)
- The Authors’ Reply (2005) (0)
- Histidine enhances transfection efficiency in vitro and ex vivo of poly ( amidoamine ) s polyplexes for intradermal DNA tattoo vaccination (2013) (0)
- Generation and validation of cytochrome P450 3A knockout and transgenic mice as tools for improved drug development and research (2004) (0)
- Bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug LL-D49194 alpha 1. (1989) (0)
- Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors (2022) (0)
- Targeted toxins (1999) (0)
- A phase II study of primary intraperitoneal paclitaxel combined with CBDCA/cytoxan (CC) in primary OC (1997) (0)
- Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography. (1994) (0)
- Baclofen overdose treated with continuous venovenous hemofiltration (2015) (0)
- Altered pharmacokinetics of vinblastine in mice with a homozygous disruption of the MDR1a P-glycoprotein gene: 2 (1994) (0)
- The use of docetaxel in continuous hyperthermic peritoneal perfusion chemotherapy (CHPPC) for peritoneal recurrence of gynecological malignancies resistant to systemic chemotherapy. A feasibility and pharmacokinetic study (2001) (0)
- Monitoring of circulating tumor DNA in non-small cell lung cancer patients treated with EGFR-inhibitors. (2017) (0)
- Acquired and intrinsic resistance to vemurafenib in BRAFV600E-driven melanoma brain metastases (2022) (0)
- Reversal of resistance to docetaxel and cabazitaxel in prostate cancer cells with ritonavir (2022) (0)
- Abstract 373: Allometric scaling of the pharmacokinetics of pegylated liposomal anticancer drugs (2011) (0)
- High lysolipid activity in malignant effusions in ovarian cancer patients (1997) (0)
- ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation (2019) (0)
- Phase I Study of Afatinib and Selumetinib in Patients with <fc><fi>KRAS</fi>â•’Mutated</fc> Colorectal, <fc>Nonâ•’Small</fc> Cell Lung, and Pancreatic Cancer (2021) (0)
- Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing (2016) (0)
- 178 POSTER Oral in vivo pharmacokinetics of the novel orally available taxane derivative BMS-275183 in wildtype and MDR1a/b double knockout mice support that BMS-275183 is a P-glycoprotein substrate drug (2006) (0)
- Phase I and Pharmacology Studies (2004) (0)
- Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS (2021) (0)
- Abstract PD08-04: Management of Hot Flashes in Breast Cancer Patients with Venlafaxine and Clonidine: A Double-Blind Placebo-Controlled Trial (2010) (0)
- The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. (2011) (0)
- P2-147 Seldi-tof MS analysis of amyloid beta peptides in CSF of patients with Alzheimer’s disease, vascular dementia and (neurological) controls: A pilot study (2006) (0)
- Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer (2019) (0)
- Transport of taxoids across the blood-brain barrier and CNS tumor penetration: a preclinical pharmacological study and clinical 'proof of concept' testing in glioma patients. (1999) (0)
- The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis. (2011) (0)
- Follow-up of Ecstasy Intoxication (1999) (0)
- Drug resistance. (2004) (0)
- Preclinical and clinical pharmacology of oral drugs (2004) (0)
- Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs. (2023) (0)
- Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism (2022) (0)
- Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet (2013) (0)
- A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens (2022) (0)
- Chapter 3 Sensitive method for plasma and tumor Ko 143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection (2012) (0)
- Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. (2020) (0)
- Stability study of concentrate-solvent mixture & infusion solutions of Jevtana® cabazitaxel for extended multi-dosing. (2021) (0)
- Reviewer ' s report Title : Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites Version : 1 Date : 15 July 2013 (2013) (0)
- Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites (2013) (0)
- Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar (2016) (0)
- Abstract LB-255: Acquired and intrinsic resistance to vemurafenib in BRAFv600e-driven melanoma brain metastases (2019) (0)
- Abstract LB-301: The impact of Abcb1 and Abcg2 on the brain penetration of PI3K-mTOR inhibitors (2010) (0)
- Ecteinascidin (ET-743) pharmacokinetics (PK)-overview of phase i and advanced phase II results (2001) (0)
- Dideoxynucleoside therapy for HIV infection (1992) (0)
- CPAA_A_292746 21..32 (2021) (0)
- Phase I and pharmacological study of AZD1152, a selective inhibitor of aurora kinase B (2009) (0)
- ET-743 A viewpoint (2002) (0)
- IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women (2021) (0)
- The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers (2013) (0)
- Last Issue of Pharmaceutisch Weekblad Scientific edition (2005) (0)
- 5033 POSTER Feasibility and pharmacokinetics of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) with paclitaxel following cytoreductive surgery in ovarian cancer patients (2007) (0)
- Prevention and therapy of tumors (2002) (0)
- The Role of ABC Transporters at the Intestinal Barrier (2009) (0)
- 325 Drug interactions with neoplastic agents (2003) (0)
- Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study (2019) (0)
- The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins (2023) (0)
- Gas chromatographic analysis, with nitrogen detection, of tocainide in plasma. (1990) (0)
- Formulation pharmaceutique d'un compose de didemnine (1999) (0)
- 35 Development of glioma-like models in mice and its application in chemotherapy intervention studies (2003) (0)
- Compositions comprising ecteinascidin and a disaccharide (2005) (0)
- Prediction of pharmacokinetic interactions between complementary, alternative medicines and (new) anticancer drugs (2007) (0)
- Clinical and pharmacological study of the novel prodrug men 4901/T-0128 in patients with solid tumors (2008) (0)
- OATP1A/1B (SLCO1A/1B) drug uptake transporters in anticancer drug pharmacokinetics and toxicity risks; possible strategies for therapy optimization (2007) (0)
- Abstracts of papers and posters Meeting on Pharmaceutical Sciences (1993) (0)
- Degradation kinetics of the investigational antitumor compound LL-D49194α1 in the presence of buffers (1994) (0)
- Preventie en therapie van tumoren (2002) (0)
- DDRE-32. ABC TRANSPORTERS RESTRICT THE BRAIN PENETRATION AND INTRACRANIAL EFFICACY OF ANTICANCER AGENTS EVEN WHEN BLOOD-BRAIN BARRIER INTEGRITY IS LOST (2020) (0)
- Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility (2005) (0)
- Development and Validation of an LC-MS/MS Assay for the Quantification of Cintirorgon (LYC-55716) in Mouse Plasma and Tissue Homogenates (2021) (0)
- PS16 - 1. The impact of Ramadan fast on BMI and cardiometabolic factors in ethnic obese adolescents (2013) (0)
- 1577PGERMLINE TYMS GENOTYPE IS HIGHLY PREDICTIVE IN PATIENTS WITH ADVANCED COLORECTAL AND GASTROESOPHAGEAL CANCER INDEPENDENT OF FLUOROPYRIMIDINE PHARMACOLOGY: RESULTS FROM TWO PROSPECTIVE TRANSLATIONAL STUDIES. (2014) (0)
- Electrochemistry of potentially bioreductive alkylating quinones. Part 4. Qualitative and quantitative structure-activity relationships of aziridinylquinones (2010) (0)
- Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study (2019) (0)
- Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar. (2004) (0)
- HIV-adsorptie- en -fusie-inhibitoren (2002) (0)
- Manufacturing of a Lyophilized Parenteral Dosage Form of the Indoloquinone Antitumor Agent EO9 for Phase II Clinical Studies in the Setting of a Hospital Pharmacy (1997) (0)
- Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose (2020) (0)
- Abstracts of papers Pharmaceutical and biomedical analysis meeting (1989) (0)
- P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure (2022) (0)
- Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology (2020) (0)
This paper list is powered by the following services:
Other Resources About Jos Beijnen
What Schools Are Affiliated With Jos Beijnen?
Jos Beijnen is affiliated with the following schools:
